12/31/23

Georgia Medical Monitoring Project Surveillance Summary, 2015–2021

Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection, Georgia Medical Monitoring Project, 2015–2021

Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection, Georgia Medical Monitoring Project, 2015–2021

Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection, Georgia Medical Monitoring Project, 2015–2021

Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection, Georgia Medical Monitoring Project, 2015–2021





The **Georgia Medical Monitoring Project Surveillance Summary, 2015–2021** is published by the Georgia Department of Public Health (DPH), HIV Epidemiology Section (HES), 200 Piedmont Ave, SE / West Tower, Suite 1002, Atlanta, Georgia 30334.

The *Georgia Medical Monitoring Project Surveillance Summary, 2015–2021*is not copyrighted and may be used and reproduced without permission. Citation of the source is, however, appreciated.

**SUGGESTED CITATION**: Georgia Department of Public Health, HIV Epidemiology Section *Medical Monitoring Project Surveillance Summary: Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection, Georgia 2015–2021,* <https://dph.georgia.gov/georgia-medical-monitoring-project-mmp>,  *Published 12/31/2023, [Accessed: date]*

**ACKNOWLEDGEMENTS:** Publication of this report was made possible with the contributions of the Georgia Medical Monitoring Project (MMP) Team, the national MMP staff at the Centers for Disease Control and Prevention (CDC), assistance from HIV care facilities, and the cooperation of participants.

Georgia MMP Team: Natalie Lucas, MPH; Kiswana Branch, MPH; Bola Griffin, MPH; Melissa Gousse, MPH; Timothy Lockhart, MPH; Shelbie Richardson MPH; and Stephen Ray, MSPH.

The report was prepared using code provided by CDC to replicate the national report, and the text is based on the national report: *Centers for Disease Control and Prevention. Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection—Medical Monitoring Project, United States, 2021 Cycle (June 2021–May 2022). HIV Surveillance Special Report 32.* https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2023. Accessed 08/31/2023.

Contents

[Commentary 6](#_Toc146271397)

[HIGHLIGHTS OF ANALYSES 6](#_Toc146271398)

[TECHNICAL NOTES 10](#_Toc146271399)

[REFERENCES 11](#_Toc146271400)

[TABLES 12](#_Toc146271401)

[Table 1. Distribution of participants across project areas—Medical Monitoring Project, Georgia, 2015–2021 13](#_Toc146271402)

[Table 2. Selected characteristics, including demographic characteristics, social determinants of health, and quality of life, among persons with diagnosed HIV infection—Medical Monitoring Project, Georgia, 2015–2021 14](#_Toc146271403)

[Table 3. Time since HIV diagnosis, stage of disease, CD4 counts, and viral suppression during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 18](#_Toc146271404)

[Table 4. Receipt of HIV care, ART prescription, PCP prophylaxis, and influenza vaccination among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 19](#_Toc146271405)

[Table 5. Sexually transmitted infection testing during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 20](#_Toc146271406)

[Table 6. Emergency department visits and hospital admissions during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 21](#_Toc146271407)

[Table 7. Antiretroviral therapy (ART) use and reasons for not taking ART among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 22](#_Toc146271408)

[Table 8. Antiretroviral therapy (ART) adherence and reasons for missing ART doses among persons with diagnosed HIV taking ART—Medical Monitoring Project, Georgia, 2015–2021 24](#_Toc146271409)

[Table 9a. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by selected demographic characteristics—Medical Monitoring Project, Georgia, 2015–2021 26](#_Toc146271410)

[Table 9b. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, Georgia, 2015–2021 28](#_Toc146271411)

[Table 10. Symptoms of depression and generalized anxiety disorder during the 2 weeks before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 29](#_Toc146271412)

[Table 11. Tobacco and electronic cigarette or other vaping device use among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 30](#_Toc146271413)

[Table 12. Alcohol use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 32](#_Toc146271414)

[Table 13. Noninjection drug use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 33](#_Toc146271415)

[Table 14. Injection drug use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 35](#_Toc146271416)

[Table 15. Receipt of Papanicolaou testing and pregnancy since HIV diagnosis among cisgender women with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 36](#_Toc146271417)

[Table 16. Sexual behavior during the 12 months before interview among cisgender men and cisgender women with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 37](#_Toc146271418)

[Table 17. Sexual behavior during the 12 months before interview among cisgender men who had sex with cisgender men (MSM), cisgender men who had sex only with cisgender women (MSW), and cisgender women who had sex with cisgender men (WSM), with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 39](#_Toc146271419)

[Table 18. Met and unmet needs for HIV ancillary services during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 41](#_Toc146271420)

[Table 19. Prevalence of physical violence by an intimate partner and forced sex among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 43](#_Toc146271421)

[Table 20. Prevention services received during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 44](#_Toc146271422)

[Table 21a. National HIV/AIDS Strategy indicators: Self-rated health and unmet needs for mental health services during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 45](#_Toc146271423)

[Table 21b. National HIV/AIDS Strategy indicators: Self-rated health and unmet needs for mental health services during the 12 months before interview among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, Georgia, 2015–2021 47](#_Toc146271424)

[Table 22a. National HIV/AIDS Strategy indicators: Unstable housing or homelessness, unemployment, and hunger/food insecurity during the 12 months before interview among persons with diagnosed HIV, overall and by demographic characteristics—Medical Monitoring Project, Georgia, 2015–2021 48](#_Toc146271425)

[Table 22b. National HIV/AIDS Strategy indicators: Unstable housing or homelessness, unemployment, hunger/food insecurity during the 12 months before interview among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, Georgia, 2015–2021 50](#_Toc146271426)

[Table 23a. National HIV/AIDS Strategy indicators: Median HIV stigma scores during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 51](#_Toc146271427)

[Table 23b. National HIV/AIDS Strategy indicators: Median HIV stigma scores during the 12 months before interview among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, Georgia, 2018-2021 53](#_Toc146271428)

[APPENDIX: METHODS AND DEFINITIONS 54](#_Toc146271429)

[METHODS 54](#_Toc146271430)

[DEFINITIONS 56](#_Toc146271431)

[HIV/AIDS RESOURCES 62](#_Toc146271432)

R

|  |
| --- |
|  |
| Commentary |
| At year-end 2021, an estimated 61,518 persons in Georgia were living with diagnosed HIV infection [1]. In 2021, the num­ber of new HIV diagnoses in Georgia was 2,412 [1]. Although the National HIV Surveillance System (NHSS) col­lects information about persons with diagnosed HIV infection [2], other surveillance systems provide more detailed information about care seeking, health care use, use of ancillary services, and other behaviors [3]. In 2005, in response to an Institute of Medicine report outlining the need for representative data on persons living with HIV [4], the Centers for Disease Control and Prevention (CDC) implemented the Medical Monitoring Project (MMP), which from 2009 to 2014 collected data from a 3-stage probability sample of persons receiving HIV medical care [5]. In 2015, in response to recommendations stemming from an Institute of Medicine review of national HIV data sys­tems [6], MMP sampling and weighting methods were revised to include all persons with diagnosed HIV infection regardless of HIV care status. MMP is a cross-sectional, nationally representative, complex sample survey that assesses the clinical and behavioral characteristics of adults with diagnosed HIV infection in the United States and Puerto Rico. The MMP samples in cycle years 2015–2021 were selected in 2 consecutive stages: (1) United States and dependent areas and (2) adults aged ≥18 years with diagnosed HIV infection reported to NHSS as of December 31, the year prior to the cycle year (ex: December 31, 2014 for the 2015 cycle). Georgia is one of a total of 23 project areas from 16 states and Puerto Rico which were funded to conduct data collection for MMP during the 2015–2021 cycles.This report presents unweighted frequencies and weighted prevalence estimates with 95% confidence intervals for selected characteristics. The estimates describe the characteristics of adults with diagnosed HIV infection who lived in Georgia as of the sampling date for the cycle year in which they participated in the Georgia MMP, hereafter referred to as persons with diagnosed HIV or persons. The period referenced is the 12 months before the participants’ interviews and medical record abstractions unless otherwise noted.Statistical software (SAS, version 9.4) was used for analysis of weighted data [7]. Data are not reported for estimates with a coefficient of variation ≥0.30. Values with an absolute confidence interval width ≥0.30, and values with an absolute confidence inter­val width between 0.05 and 0.30 and a relative confi­dence interval width >130% are marked with an asterisk and should be interpreted with caution. No statistical tests were performed. Additional informa­tion on MMP is available at [https://www.cdc.gov/hiv/statistics/ systems/mmp/index.html](https://www.cdc.gov/hiv/statistics/%20systems/mmp/index.html).HIGHLIGHTS OF ANALYSES**Response Rates**In total, 3,500 persons considered to be residents of Georgia were sampled from NHSS for cycle years 2015–2021, and 1,178 participated (Table 1). Adjusted for eligibility, the response rates were 33.5% (2015), 43.9% (2016), 44.6% (2017), 36.6% (2018), 45.8% (2019), 39.7% (2020), and 39.1% (2021).**Sociodemographic Characteristics**An estimated 75% of persons were male, 24% were female and about 2% were transgender (Table 2). Approximately 42% of persons identified themselves as heterosexual or straight; 44% as lesbian or gay; 11% as bisexual; and 3% as another sexual orientation. An estimated 71% were Black or African American, 19% were White, and 5% were Hispanic or Latino. Two-thirds (67%) were aged at least 40 years. Over half (63%) had more than a high school educa­tion and 95% were born in a U.S. state or territory. The estimated prevalence of homelessness among all persons with diagnosed HIV was 9%. About 21% of persons indicated that they had some form of housing instability. An estimated 98% had health insurance or coverage for antiretrovi­ral therapy (ART) medications: 43% had coverage through the Ryan White HIV/AIDS Program, 29% had Medicaid, 40% had private health insurance, and 27% had Medicare. An estimated 39% had a disabil­ity, 43% were unemployed, and 34% had household incomes at or below the federal poverty threshold. An estimated 17% received Supplemental Security Income (SSI) and 21% received Social Security Dis­ability Insurance (SSDI). **Clinical Characteristics** According to the CDC stage of disease classification for HIV infection [8], an estimated 53% of persons had ever had stage 3 (AIDS) disease (Table 3). An estimated 9% of persons had a geometric mean CD4 T-lymphocyte (CD4) count of 0–199 cells/μL. The estimated average geometric mean CD4 count among all persons was 595 cells/μL, and the median geomet­ric mean CD4 count was 565 cells/μL (range: 2–2,124) (data not shown in table). An estimated 70% of persons had an undetectable (<200 copies/mL) HIV viral load at the most recent mea­surement, while 62% of persons had undetectable viral loads at all measurements during the past 12 months (durable/sustained viral suppression). **Use of Health Care Services**Overall, 97% had received outpatient HIV care during the past 12 months, and 99% had received outpatient HIV care during the past 24 months (Table 4). An estimated 80% were retained in care (having at least two HIV-related care visits at least three months apart during the year) during the past 12 months, while 60% were retained in care during the past 24 months. An estimated 83% of persons had an ART prescription documented in the medical record during the 12 months before the interview. Of persons who met the clinical criteria for *Pneumocystis* pneumonia (PCP) prophylaxis, 40% had a prescrip­tion for PCP prophylaxis documented in the medical record. Among sexually active persons, an estimated 55% were tested for gonorrhea, 56% for chlamydia, 69% for syphilis, and 50% for all 3 sexually transmitted diseases (STDs) (Table 5). An estimated 43% of persons were seen in an emergency department at least once, and 4% were seen at least 5 times (Table 6). An estimated 20% of persons were admitted to a hospital for an illness at least once.**Self-reported ART Medication Use and Adherence**An estimated 92% of persons were currently taking ART based on self-report (Table 7). Among the esti­mated 2% of persons without a history of ART use, 60%\* had never taken ART because a health care pro­vider advised a delay in treatment. Among the esti­mated 8% of persons with a history of ART use who were not currently taking ART, 56% were not taking ART due to money or insurance problems. (\* indicating percentage should be interpreted with caution)Among persons taking ART, 58% took all of their ART doses in the past 30 days (Table 8). Among per­sons taking ART, 70% had never been troubled by ART side effects during the past 30 days; 16% had rarely been troubled. The most common reasons given for not taking ones most recently missed ART dose were forgetting (50%) and a change in one’s daily routine or being out of town (37%). **Clinical Characteristics by Subgroups**The estimated prevalence of ART prescription docu­mented in a medical record was 83% among males and 82% among females (Table 9a). An estimated 83% of Black or African Americans were prescribed ART, compared with 74% of Hispanics or Latinos and 83% of Whites. The estimated prevalence of ART prescrip­tion was 77% among persons aged 18 to 29 years and 85% among those aged 50 years or older. The estimated prevalence of durable viral sup­pression was 62% among males and 61% among females. An estimated 59% of Black or African Americans had durable viral suppression, compared with 55% of Hispanics or Latinos and 73% of Whites. The estimated prevalence of durable viral suppres­sion was 42% among persons aged 18 to 29 years and 71% among those aged 50 years or older. **Depression and Substance Use**The estimated prevalence of major or other depres­sion in the past 2 weeks based on the Patient Health Questionnaire (PHQ-8) algorithm [9] was 17%, including 9% with major depression (Table 10). Based on the total PHQ-8 symptom score (see the appendix), an estimated 14% of persons had moder­ate or severe depression. The estimated prevalence of mild, moderate, or severe anxiety in the past 2 weeks based on the Generalized Anxiety Disorder Scale (GAD-7) [10] was 22%, including 8% with severe anxiety. The estimated prevalence of current smoking was 31%: 25% of persons smoked daily, and 2% less than monthly (Table 11). The estimated prevalence of alcohol use was 67%: 7% of persons drank alcohol daily, 21% weekly, 12% monthly, and 28% less than monthly (Table 12). An estimated 16% of persons engaged in binge drinking during the past 30 days. An estimated 35% of persons used noninjection drugs for nonmedical purposes (Table 13). In total, an estimated 31% used marijuana, 8% used poppers (amyl nitrite), 6% used cocaine, 4% used methamphetamines, and 3% used prescription opioids. Almost all persons did not use injection drugs for nonmedical purposes (Table 14). **Gynecologic and Reproductive Health**Among females, 88% reported receiving a Papanicolaou (Pap) test in the past three years (Table 15). An estimated 29% of females reported being pregnant at least once since testing positive for HIV infection. **Sexual Behavior**An estimated 52% of cisgender men had anal sex with men (Table 16). Of those cisgender men who had anal sex with men, 3% considered themselves straight, 78% considered themselves gay, 16% considered themselves bisexual, and 3% considered themselves some other sexual orientation. An estimated 30% of men did not have vaginal or anal sex. Among women, 57% had vaginal or anal sex, 43% did not have vaginal or anal sex. An estimated 7% of men who had sex with men and about 9% of women who had sex with men engaged in high-risk sex (Table 17). High-risk sex is defined as engaging in any type of condomless sexual activity while not having durable viral suppression and whose partner(s) is not HIV-positive. In terms of prevention strategies among sexually active persons, an estimated 60% of men who had sex with men engaged in sex while sustainably virally suppressed, 48% had condom-protected sex, and 66% had sex with an HIV-positive part­ner. Among sexually active men who had sex only with women, 61% engaged in sex while sustainably virally suppressed, 65%\* had condom-protected sex, and 28% had sex with an HIV-positive partner. Among sexually active women who had sex with men, 58% engaged in sex while sustainably virally suppressed, 43%\* had condom-protected sex, and 29% had sex with an HIV-positive partner. **Met and Unmet Need for Ancillary Services**An estimated 49% of persons received dental care; 45% received HIV case management services; 43% received medicine through the AIDS Drug Assistance Program (ADAP); and 40% received services through the Supplemental Nutrition Assistance Program (SNAP) or Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) (Table 18). An estimated 31% of persons had unmet needs for dental care; 15% for SNAP or WIC; 15% for shelter or housing services; 11% for meal or food services; 10% for mental health services; 10% for HIV case man­agement services; 10% for transportation assistance; 8% for HIV peer group support; and 5% for patient navigation services. **Intimate Partner Violence and Sexual Violence**An estimated 26% of persons had ever been physi­cally hurt by a romantic or sexual partner, including 4% who experienced this in the past 12 months (Table 19). An estimated 16% of persons had ever been threatened with harm or physically forced to have unwanted sex. **Prevention Activities**An estimated 55% of persons received counseling from a physician, nurse, or other health care worker about HIV and STD risk reduction, and 27% of persons had a one-on-one conversation with an outreach worker, a counselor, or a prevention program worker about pre­vention (Table 20). An estimated 47% of persons received free condoms from various organizations. **Division of HIV/AIDS Prevention National Indicators**Regarding beliefs about self-rated health, 74% of males rated themselves as having good or better health. For females, 62% rated themselves as having good or better health (Table 21a). Among those who identified as heterosexual or straight, 61% indicated having good or better health; while among those who identified as lesbian or gay, 78% indicated having good or better health. Among all MSM, 79% reported good health; Black or African American MSM, 81% reported good health; Hispanic or Latino MSM, 75%\* reported good health; Black or African American cisgender women, 61% reported good health. The estimated prevalence of unstable housing or homelessness among persons who received outpatient HIV care in the past 12 months was 23% (Table 22a). The estimated prevalence of unemployment was 15%. The estimated prevalence of problems with hunger or food security was 18%. The median HIV stigma score (Table 23a) among all persons was 29. |

|  |
| --- |
|  |
| TECHNICAL NOTES |
| **POPULATION OF INFERENCE**For the 2015–2021 Medical Monitoring Project (MMP) data collection cycles (data collected June 1–May 31, each year), the population of inference was adults with diagnosed HIV (aged ≥18 years) living in Georgia as of December 31st of the year prior to the start of the data collection cycle.**DATA COLLECTION**Persons with diagnosed HIV were sampled for MMP using data from the National HIV Surveillance Sys­tem (NHSS). Sampled persons were recruited to par­ticipate in person, by telephone, or by mail. To be eligible for MMP, the person had to be, as of Decem­ber 31 of the year prior to the data collection cycle: living with diagnosed HIV infection, aged ≥18 years, and residing in Georgia.A trained interviewer conducted either a computer-assisted telephone interview or an in-person interview. Persons who agreed to participate were interviewed over the telephone or in a private location (e.g., at home or in a clinic). The interview (approximately 45 minutes) included questions about demographics, health care use, met and unmet needs for ancillary services, sexual behavior, depression and anxiety, gynecologic and reproductive history (females only), drug and alcohol use, and use of prevention services. Participants were given a token of appreciation of $50 (2015, 2018, 2019, 2020, and 2021 cycle) or $75 (2016 and 2017 cycles) in cash or the equivalent for partic­ipation. |

|  |
| --- |
|  |
| REFERENCES |
| 1. Georgia Department of Public Health, HIV Epidemiology Section HIV Surveillance Summary, Georgia 2021, [https://dph.georgia.gov/epidemiology/georgias-hivaids-epidemiology-section/georgia-hiv-surveillance-data](https://dph.georgia.gov/data-fact-sheet-summaries), Published March 2023, Accessed: 09/23/2023.
2. Nakashima AK, Fleming PL. HIV/AIDS surveillance in the United States, 1981–2001. *J Acquir Immune Defic Syndr* 2003;32(suppl 1):S68–S85.
3. McNaghten AD, Wolfe MI, Onorato I, et al. Improving the representativeness of behavioral and clinical sur­veillance for persons with HIV in the United States: the rationale for developing a population-based approach. *PLoS One* 2007;2(6):e550.
4. Institute of Medicine. *Measuring What Matters: Allocation, Planning and Quality Assessment for the Ryan White CARE Act*. Washington, DC: National Academies Press; 2004. https://www.nap.edu/read/ 10855. Published November 7, 2003. Accessed January 11, 2019.
5. CDC*. Behavioral and Clinical Characteristics of Persons with Diagnosed HIV Infection—Medical Monitoring Project, United States, 2021 Cycle (June 2021–May 2022). HIV Surveillance Special Report 32*. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2022. Accessed 09/23/2022.
6. Institute of Medicine. *Monitoring HIV Care in the United States: Indicators and Data Systems*. Washing­ton, DC: National Academies Press; 2012. doi:10.17226/13225.
7. SAS Institute Inc. SAS version 9.4. Cary, NC: SAS Institute; 2011.
8. CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case defini­tion for HIV infection—United States, 2014. *MMWR* 2014;63(RR-03):1–10. https://www.cdc.gov/mmwr/ indrr\_2014.html. Accessed January 11, 2019.
9. Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the general popula­tion. *J Affect Disord* 2009;114(1–3):163–173.
10. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166(10):1092–1097.
 |

|  |
| --- |
|  |
| TABLES |

|  |
| --- |
| Table 1. Distribution of participants across project areas—Medical Monitoring Project, Georgia, 2015–2021 |
| **Project Area** | **No. sampled** | **No. participating** | **% participatinga** | **% of total** |
| Georgia | 3,500 | 1,369 | 39.1 | 4.9 |
| Note. Percentages might not sum to 100 because of rounding. |
| a Calculated by dividing number of participating respondents by the total number of persons sampled. |
|  |

|  |
| --- |
| Table 2. Selected characteristics, including demographic characteristics, social determinants of health, and quality of life, among persons with diagnosed HIV infection—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Demographic characteristics** |  |  |  |
|  |  |  |  |
| **Age at time of interview (years)** |  |  |  |
| 18–24 | 37 | 2.7 | 1.8–3.6 |
| 25–29 | 111 | 8.5 | 6.9–10.2 |
| 30–34 | 145 | 11.2 | 9.4–13.0 |
| 35–39 | 138 | 10.7 | 8.9–12.5 |
| 40–44 | 145 | 10.6 | 8.9–12.4 |
| 45–49 | 152 | 11.1 | 9.3–12.9 |
| 50–54 | 233 | 15.9 | 13.9–17.9 |
| 55–59 | 212 | 14.5 | 12.5–16.4 |
| 60–64 | 102 | 8.0 | 6.3–9.6 |
| ≥65 | 94 | 6.9 | 5.5–8.3 |
| **Race/ethnicity** |  |  |  |
| American Indian/Alaska Native | -- | -- | -- |
| Asian | -- | -- | -- |
| Black/African American | 1,008 | 71.2 | 68.5–73.9 |
| Hispanic/Latinod | 66 | 5.2 | 3.8–6.5 |
| Native Hawaiian/other Pacific Islander | -- | -- | -- |
| White | 224 | 18.5 | 16.1–20.8 |
| Multiple races | 65 | 4.7 | 3.5–6.0 |
| **Gender** |  |  |  |
| Cisgender male | 987 | 74.5 | 72.1–76.9 |
| Cisgender female | 356 | 23.9 | 21.5–26.2 |
| Transgendere | 24 | 1.6 | 0.9–2.3 |
| **Sexual Orientation** |  |  |  |
| Lesbian or gay | 563 | 43.9 | 41.0–46.8 |
| Heterosexual or straight | 611 | 42.4 | 39.6–45.2 |
| Bisexual | 139 | 11.0 | 9.1–12.8 |
| Other | 39 | 2.7 | 1.8–3.5 |
|  |  |  |  |
| **Measures of housing instability** |  |  |  |
|  |  |  |  |
| **Unstable housing at any time, past 12 monthsf** |  |  |  |
| Yes | 170 | 20.6 | 17.6–23.5 |
| No | 614 | 79.4 | 76.5–82.4 |
| **Homeless at any time, past 12 monthsg** |  |  |  |
| Yes | 123 | 8.6 | 7.1–10.2 |
| No | 1,236 | 91.4 | 89.8–92.9 |
| **Unstable housing or homelessness, past 12 monthsh** |  |  |  |
| Yes | 186 | 22.5 | 19.5–25.6 |
| No | 598 | 77.5 | 74.4–80.5 |
| **Hunger/food insecurityi** |  |  |  |
| Yes | 246 | 18.1 | 15.9–20.2 |
| No | 1,112 | 81.9 | 79.8–84.1 |
| **Employment statusj** |  |  |  |
| Employed | 615 | 46.6 | 43.7–49.4 |
| Unemployed or unable to work | 606 | 43.1 | 40.3–45.9 |
| Student | 29 | 2.5 | 1.5–3.5 |
| Retired | 108 | 7.8 | 6.3–9.4 |
| **Combined yearly household income (US$)k** |  |  |  |
| 0–19,999 | 572 | 44.6 | 41.7–47.6 |
| 20,000–39,999 | 314 | 25.1 | 22.5–27.6 |
| 40,000–74,999 | 241 | 20.1 | 17.7–22.6 |
| ≥75,000 | 122 | 10.2 | 8.4–12.0 |
| **Poverty guidelinesl** |  |  |  |
| <100% FPL | 446 | 34.2 | 31.4–37.0 |
| 100–138% FPL | 141 | 11.5 | 9.6–13.5 |
| 139–399% FPL | 489 | 39.9 | 37.0–42.8 |
| ≥400% FPL | 173 | 14.4 | 12.2–16.5 |
| **Received Supplemental Security Income (SSI), past 12 months** |  |  |  |
| Yes | 134 | 17.3 | 14.4–20.2 |
| No | 637 | 82.7 | 79.8–85.6 |
| **Received Social Security Disability Insurance (SSDI), past 12 months** |  |  |  |
| Yes | 157 | 20.7 | 17.6–23.8 |
| No | 615 | 79.3 | 76.2–82.4 |
|  |  |  |  |
| **Education** |  |  |  |
|  |  |  |  |
| **Educational attainment** |  |  |  |
| Less than high school | 194 | 12.9 | 11.1–14.8 |
| High school diploma or GED | 335 | 24.5 | 22.0–26.9 |
| More than high school | 830 | 62.6 | 59.9–65.4 |
|  |  |  |  |
| **Health-related factors** |  |  |  |
|  |  |  |  |
| **Confidence in completing health forms** |  |  |  |
| Extremely | 823 | 60.5 | 57.7–63.3 |
| Quite a bit | 215 | 15.8 | 13.8–17.9 |
| Somewhat | 155 | 11.9 | 10.0–13.8 |
| A little bit | 99 | 7.0 | 5.5–8.4 |
| Not at all | 65 | 4.8 | 3.6–6.0 |
| **Self-rated health** |  |  |  |
| Poor | 46 | 5.8 | 4.0–7.6 |
| Fair | 181 | 23.2 | 20.0–26.4 |
| Good | 290 | 37.0 | 33.4–40.7 |
| Very good | 165 | 21.2 | 18.1–24.2 |
| Excellent | 103 | 12.8 | 10.3–15.4 |
| **Any disabilitym** |  |  |  |
| Yes | 542 | 39.2 | 36.4–42.0 |
| No | 817 | 60.8 | 58.0–63.6 |
|  |  |  |  |
| **Type of health insurance or coverage for care or medications, past 12 monthsn** |  |  |  |
|  |  |  |  |
| **Health insurance or coverage for care or medications (including Ryan White HIV/AIDS Program [RWHAP] assistance), past 12 monthsn** |  |  |  |
| Yes | 1,331 | 97.6 | 96.6–98.6 |
| No | 24 | 2.4 | 1.4–3.4 |
| **Ryan White HIV/AIDS Program assistance** |  |  |  |
| Yes | 613 | 43.1 | 40.3–46.0 |
| No | 725 | 56.9 | 54.0–59.7 |
| **Medicaid** |  |  |  |
| Yes | 410 | 29.1 | 26.5–31.7 |
| No | 942 | 70.9 | 68.3–73.5 |
| **Medicare** |  |  |  |
| Yes | 371 | 27.3 | 24.8–29.9 |
| No | 970 | 72.7 | 70.1–75.2 |
| **Private health insuranceo** |  |  |  |
| Yes | 522 | 39.9 | 37.1–42.7 |
| No | 817 | 60.1 | 57.3–62.9 |
| **Other public insurancep** |  |  |  |
| Yes | 42 | 3.0 | 2.0–3.9 |
| No | 1,296 | 97.0 | 96.1–98.0 |
| **Tricare/CHAMPUS or Veterans Administration** |  |  |  |
| Yes | 56 | 5.3 | 3.8–6.8 |
| No | 1,278 | 94.7 | 93.2–96.2 |
| **Insurance type unknownq** |  |  |  |
| Yes | -- | -- | -- |
| No | 1,328 | 99.2 | 98.6–99.7 |
| **Uninsuredr** |  |  |  |
| Yes | 290 | 21.1 | 18.8–23.4 |
| No | 1,065 | 78.9 | 76.6–81.2 |
|  |  |  |  |
| **Social and community context** |  |  |  |
|  |  |  |  |
| **Country or territory of birth** |  |  |  |
| US state or territory | 1,296 | 95.4 | 94.2–96.6 |
| Outside the US and its territories | 62 | 4.6 | 3.4–5.8 |
| **Incarcerated >24 hours, past 12 months** |  |  |  |
| Yes | 81 | 5.6 | 4.4–6.9 |
| No | 1,277 | 94.4 | 93.1–95.6 |
|  |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviations: CI, confidence interval; GED, general educational development; FPL, federal poverty level; CHAMPUS, Civilian Health and Medical Program of the Uniformed Services; US$, US dollar; HHS, Department of Health and Human Services [footnotes only]. |
| Note. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category. |
| e Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. |
| f Defined as moving in with others due to financial issues, moving 2 or more times, or being evicted at any time during the past 12 months. |
| g Defined as living on the street, in a shelter, in a single-room–occupancy hotel, or in a car at any time during the past 12 months. |
| h Defined as experiencing unstable housing (i.e., moving in with others due to financial issues, moving 2 or more times, or being evicted) or homelessness (living on the street, in a shelter, in a single-room–occupancy hotel, or in a car) at any time during the past 12 months. |
| i “Hunger/food insecurity” defined as going without food due to lack of money during the past 12 months. |
| j Employed includes employed for wages, self-employed, or homemaker. |
| k Income from all sources, before taxes, in the last calendar year. |
| l Poverty guidelines as defined by HHS; the 2020 guidelines were used for persons interviewed in 2021 and the 2021 guidelines were used for persons interviewed in 2022. More information regarding HHS poverty guidelines can be found at https://aspe.hhs.gov/frequently-asked-questions-related-poverty-guidelines-and-poverty. |
| m Includes physical, mental, and emotional disabilities. |
| n Persons could select more than 1 response for health insurance or coverage for care or medications (including antiretroviral medications). |
| o Defined as receiving health insurance through a person’s employer or a family member’s employer, or purchased through the Health Insurance Marketplace or directly from a health insurance company. |
| p Other public insurance included city, county, state, or other publicly funded insurance, not including Medicaid. |
| q Unknown insurance type means that the person had health insurance or coverage for care or medications (including antiretroviral medications), but the type of insurance or coverage could not be determined. |
| r Includes those who did not report having any insurance, or received RWHAP assistance only, without coverage through any other insurance categories. |

|  |
| --- |
| Table 3. Time since HIV diagnosis, stage of disease, CD4 counts, and viral suppression during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Time since HIV diagnosis (years)d** |  |  |  |
| <5 | 221 | 16.7 | 14.5–18.8 |
| 5–9 | 337 | 25.7 | 23.1–28.2 |
| ≥10 | 807 | 57.7 | 54.8–60.5 |
| **HIV infection stage 3 (AIDS)e** |  |  |  |
| Yes | 767 | 53.1 | 50.2–55.9 |
| No | 598 | 46.9 | 44.1–49.8 |
| **Geometric mean CD4 count (cells/µL)** |  |  |  |
| 0–199 | 109 | 8.9 | 7.2–10.6 |
| 200–349 | 149 | 13.3 | 11.2–15.4 |
| 350–499 | 187 | 16.7 | 14.3–19.0 |
| ≥500 | 674 | 61.1 | 58.1–64.1 |
| **Lowest CD4 count (cells/µL), past 12 months** |  |  |  |
| 0–49 | 43 | 3.5 | 2.4–4.6 |
| 50–199 | 92 | 7.7 | 6.1–9.3 |
| 200–349 | 182 | 16.1 | 13.8–18.3 |
| 350–499 | 216 | 19.0 | 16.5–21.4 |
| ≥500 | 593 | 53.7 | 50.6–56.8 |
| **Viral suppression** |  |  |  |
| Most recent viral load documented undetectable or <200 copies/mL | 967 | 69.5 | 66.8–72.2 |
| Most recent viral load documented detectable, ≥200 copies/mL, or missing/unknown | 402 | 30.5 | 27.8–33.2 |
| **Sustained viral suppression** |  |  |  |
| All viral load measurements documented undetectable or <200 copies/mL | 855 | 61.5 | 58.7–64.3 |
| Any viral load ≥200 copies/mL or missing/unknown | 514 | 38.5 | 35.7–41.3 |
| – |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviations: CD4, CD4 T-lymphocyte count (cells/µL); CI, confidence interval; CDC, Centers for Disease Control and Prevention [footnotes only]. |
| Source of disease stage information: CDC. Revised surveillance case definition for HIV infection–United States, 2014. MMWR 2014;63(RR-03):1–10. https://www.cdc.gov/mmwr/indrr\_2014.html. Accessed [XX]. |
| Note. CD4 counts and viral load measurements are from medical record abstraction. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Determined based on date of HIV diagnosis from the National HIV Surveillance System. |
| e HIV infection, stage 3 (AIDS): documentation of an AIDS-defining condition or either a CD4 count of <200 cells/µL or a CD4 percentage of total lymphocytes of <14. Documentation of an AIDS-defining condition supersedes a CD4 count or percentage that would not, by itself, be the basis for a stage 3 (AIDS) classification. |

|  |
| --- |
| Table 4. Receipt of HIV care, ART prescription, PCP prophylaxis, and influenza vaccination among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Ever received outpatient HIV cared** |  |  |  |
| Yes | 1,364 | 99.6 | 99.3–100.0 |
| No | -- | -- | -- |
| **Received outpatient HIV care, past 12 monthsd** |  |  |  |
| Yes | 1,339 | 97.1 | 96.0–98.3 |
| No | 27 | 2.9 | 1.7–4.0 |
| **Received outpatient HIV care, past 24 monthsd** |  |  |  |
| Yes | 1,356 | 99.3 | 98.9–99.8 |
| No | -- | -- | -- |
| **Retained in care, past 12 monthse** |  |  |  |
| Yes | 1,073 | 79.6 | 77.2–82.1 |
| No | 245 | 20.4 | 17.9–22.8 |
| **Retained in care, past 24 monthse** |  |  |  |
| Yes | 797 | 60.0 | 57.2–62.9 |
| No | 518 | 40.0 | 37.1–42.8 |
| **Missed ≥1 HIV care visits, past 12 months** |  |  |  |
| Yes | 174 | 22.3 | 19.1–25.5 |
| No | 607 | 77.7 | 74.5–80.9 |
| **Prescribed ART, past 12 monthsf** |  |  |  |
| Yes | 1,158 | 83.0 | 80.7–85.3 |
| No | 211 | 17.0 | 14.7–19.3 |
| **Prescribed PCP prophylaxis, past 12 monthsg** |  |  |  |
| Yes | 52 | 39.7 | 30.8–48.6 |
| No | 79 | 60.3 | 51.4–69.2 |
| **Received influenza vaccination, past 12 months** |  |  |  |
| Yes | 573 | 73.2 | 69.9–76.5 |
| No | 211 | 26.8 | 23.5–30.1 |
| – |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviations: CI, confidence interval; ART, antiretroviral therapy; PCP, *Pneumocystis* pneumonia. |
| *Note.* CD4 counts, viral load measurements, and prophylaxes are from medical record abstraction. Influenza vaccination was obtained through interview. Measurement period is the 12 months before interview unless otherwise noted. |
| Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Outpatient HIV care was defined as any documentation of the following: encounter with an HIV care provider, viral load test result, CD4 test result, HIV resistance test or tropism assay, ART prescription, PCP prophylaxis, or MAC prophylaxis. |
| e Two elements of outpatient HIV care at least 90 days apart in each 12-month period. |
| f ART prescription documented in medical record; persons with no medical record abstraction were considered to have no documentation of ART prescription. |
| g Among persons with CD4 cell count <200 cells/µL. |

|  |
| --- |
| Table 5. Sexually transmitted infection testing during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Total population** | **Sexually activea persons only** |
|  | **No.b** | **col %c** | **95% CId** | **No.b** | **col %c** | **95% CId** |
| **Gonorrheae** |  |  |  |  |  |  |
| Yes, received test | 632 | 49.5 | 46.6–52.5 | 452 | 55.3 | 51.7–58.9 |
| No test documented | 646 | 50.5 | 47.5–53.4 | 363 | 44.7 | 41.1–48.3 |
| **Chlamydiaf** |  |  |  |  |  |  |
| Yes, received test | 633 | 49.7 | 46.7–52.6 | 453 | 55.5 | 51.8–59.1 |
| No test documented | 645 | 50.3 | 47.4–53.3 | 362 | 44.5 | 40.9–48.2 |
| **Syphilisg** |  |  |  |  |  |  |
| Yes, received test | 839 | 65.6 | 62.8–68.4 | 569 | 69.1 | 65.7–72.6 |
| No test documented | 439 | 34.4 | 31.6–37.2 | 246 | 30.9 | 27.4–34.3 |
| **Gonorrhea, chlamydia, and syphilis** |  |  |  |  |  |  |
| Yes, received all 3 tests | 564 | 44.5 | 41.5–47.4 | 412 | 50.3 | 46.6–53.9 |
| Fewer than 3 tests documented | 714 | 55.5 | 52.6–58.5 | 403 | 49.7 | 46.1–53.4 |
| – |  |  |  |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |  ***874*** | ***100*** |  |
| Abbreviations: CI, confidence interval; DFA, direct fluorescent antibody [footnotes only]; EIA, enzyme immunoassay [footnotes only]; ELISA, enzyme-linked immunoassay [footnotes only]; FTA-ABS, fluorescent treponemal antibody absorbed [footnotes only]; MHA-TP, microhemagglutination assay for antibody to *Treponema pallidum* [footnotes only]; NAAT, nucleic acid amplification test [footnotes only]; RPR, rapid plasma reagin [footnotes only]; TP-PA, *T. pallidum* particle agglutination [footnotes only]; TPHA, *T. pallidum* hemagglutination assay [footnotes only]; VDRL, Venereal Disease Research Laboratory [footnotes only]. |
| *Note.* Information on laboratory testing for sexually transmitted infections was based on medical record abstraction. |
| Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Sexual activity was reported in the interview component of the Medical Monitoring Project and was defined as anal or vaginal intercourse during the 12 months prior to interview. |
| b Numbers are unweighted. |
| c Percentages are weighted percentages. |
| d CIs incorporate weighted percentages. |
| e Testing for *Neisseria gonorrhoeae* was defined as documentation of a result from culture, DFA, gram stain, EIA or ELISA, NAAT, or nucleic acid probe performed on a specimen from any anatomical site for screening or diagnostic purposes. |
| f *Chlamydia trachomatis* testing was defined as a result from DFA, EIA or ELISA, NAAT, or nucleic acid probe performed on a specimen from any anatomical site for screening or diagnostic purposes. |
| g Syphilis testing was defined as a result from nontreponemal syphilis tests (RPR or VDRL), treponemal syphilis tests (TPHA, TP-PA, MHA-TP, or FTA-ABS tests), or dark-field microscopy performed for screening or diagnostic purposes. |

|  |
| --- |
| Table 6. Emergency department visits and hospital admissions during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Number of visits to emergency department** |  |  |  |
| 0 | 762 | 56.7 | 53.8–59.5 |
| 1 | 269 | 20.2 | 17.9–22.6 |
| 2–4 | 265 | 19.1 | 16.9–21.3 |
| ≥5 | 56 | 4.0 | 2.9–5.1 |
| **Number of hospital admissions** |  |  |  |
| 0 | 1,081 | 80.4 | 78.1–82.7 |
| 1 | 178 | 13.2 | 11.2–15.1 |
| 2–4 | 80 | 5.6 | 4.3–6.9 |
| ≥5 | 13 | 0.8 | 0.3–1.2 |
| – |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviation: CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |

|  |
| --- |
| Table 7. Antiretroviral therapy (ART) use and reasons for not taking ART among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Ever taken ART** |  |  |  |
| Yes | 1,332 | 98.2 | 97.3–99.1 |
| No | 18 | 1.8 | 0.9–2.7 |
| **Currently taking ART** |  |  |  |
| Yes | 1,264 | 92.2 | 90.6–93.9 |
| No | 90 | 7.8 | 6.1–9.4 |
|  |  |  |  |
| **Reasons for never taking ARTd** |  |  |  |
|  |  |  |  |
| **Health care provider said person should not start taking ART** |  |  |  |
| Yes | 10 | 59.3\* | 32.3–86.3 |
| No | -- | -- | -- |
| **Person did not believe they needed ART** |  |  |  |
| Yes | -- | -- | -- |
| No | 11 | 65.4\* | 39.0–91.8 |
| **Money or insurance problems** |  |  |  |
| Yes | -- | -- | -- |
| No | 12 | 72.4\* | 48.7–96.2 |
| **Person thinks ART would make them feel sick or harm them** |  |  |  |
| Yes | -- | -- | -- |
| No | 12 | 75.9\* | 54.4–97.3 |
| **Health care provider never discussed taking ART with person** |  |  |  |
| Yes | -- | -- | -- |
| No | 14 | 87.4 | 70.7–100.0 |
|  |  |  |  |
| **Reasons for not currently taking ART, among those persons with a history of ART used** |  |  |  |
|  |  |  |  |
| **Money or insurance problems** |  |  |  |
| Yes | 35 | 56.0 | 43.3–68.8 |
| No | 33 | 44.0 | 31.2–56.7 |
| **Health care provider never discussed restarting ART with person** |  |  |  |
| Yes | 11 | 21.2 | 9.5–32.9 |
| No | 57 | 78.8 | 67.1–90.5 |
| **Person thinks ART would make them feel sick or harm them** |  |  |  |
| Yes | 14 | 19.6 | 9.6–29.7 |
| No | 54 | 80.4 | 70.3–90.4 |
| **Person did not believe they needed ART** |  |  |  |
| Yes | 11 | 18.1 | 7.6–28.5 |
| No | 57 | 81.9 | 71.5–92.4 |
| **Health care provider said person should not take ART** |  |  |  |
| Yes | -- | -- | -- |
| No | 60 | 95.0 | 87.8–100.0 |
| \_ |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviation: CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Persons could select more than 1 response for reasons not taking ART. |

|  |
| --- |
| Table 8. Antiretroviral therapy (ART) adherence and reasons for missing ART doses among persons with diagnosed HIV taking ART—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **ART adherence in the past 30 days** |  |  |  |
|  |  |  |  |
| **How many days did you miss at least 1 dose of any of your HIV medicines?** |  |  |  |
| 0 | 738 | 58.4 | 55.5–61.4 |
| 1–2 | 339 | 26.6 | 24.0–29.2 |
| 3–5 | 120 | 9.9 | 8.1–11.7 |
| 6–10 | 35 | 2.7 | 1.8–3.6 |
| ≥11 | 29 | 2.4 | 1.5–3.3 |
| **How well did you do at taking your HIV medicines in the way you were supposed to?** |  |  |  |
| Very poor | -- | -- | -- |
| Poor | 24 | 1.8 | 1.0–2.6 |
| Fair | 53 | 4.3 | 3.0–5.6 |
| Good | 167 | 13.2 | 11.2–15.3 |
| Very good | 365 | 28.6 | 25.9–31.2 |
| Excellent | 643 | 51.2 | 48.2–54.1 |
| **How often did you take your HIV medicines in the way you were supposed to?** |  |  |  |
| Never | -- | -- | -- |
| Rarely | -- | -- | -- |
| Sometimes | 26 | 1.8 | 1.0–2.6 |
| Usually | 55 | 4.4 | 3.2–5.7 |
| Almost always | 352 | 28.3 | 25.6–31.0 |
| Always | 813 | 64.0 | 61.2–66.9 |
| **How often were you troubled by ART side effects?** |  |  |  |
| Never | 886 | 69.9 | 67.2–72.7 |
| Rarely | 197 | 16.2 | 13.9–18.4 |
| About half of the time | 81 | 6.8 | 5.2–8.3 |
| Most of the time | 48 | 3.7 | 2.6–4.8 |
| Always | 41 | 3.4 | 2.3–4.5 |
|  |  |  |  |
| **Reasons for last missed ART dose among persons who ever missed a dosed** |  |  |  |
|  |  |  |  |
| **Forgot to take HIV medicines** |  |  |  |
| Yes | 511 | 50.5 | 47.3–53.7 |
| No | 529 | 49.5 | 46.3–52.7 |
| **Change in your daily routine or were out of town** |  |  |  |
| Yes | 381 | 37.3 | 34.2–40.5 |
| No | 659 | 62.7 | 59.5–65.8 |
| **Fell asleep early or overslept** |  |  |  |
| Yes | 338 | 32.5 | 29.4–35.5 |
| No | 700 | 67.5 | 64.5–70.6 |
| **Had a problem getting a prescription or a refill for HIV medicines** |  |  |  |
| Yes | 104 | 19.2 | 15.6–22.8 |
| No | 416 | 80.8 | 77.2–84.4 |
| **Felt depressed or overwhelmed** |  |  |  |
| Yes | 129 | 12.5 | 10.3–14.7 |
| No | 911 | 87.5 | 85.3–89.7 |
| **Had side effects from your HIV medicines** |  |  |  |
| Yes | 97 | 9.9 | 7.9–11.9 |
| No | 942 | 90.1 | 88.1–92.1 |
| **Did not feel like taking HIV medicines** |  |  |  |
| Yes | 91 | 8.2 | 6.5–10.0 |
| No | 950 | 91.8 | 90.0–93.5 |
| **Had a problem paying for HIV medicines** |  |  |  |
| Yes | 42 | 7.3 | 5.1–9.6 |
| No | 478 | 92.7 | 90.4–94.9 |
| **Was drinking or using drugs** |  |  |  |
| Yes | 71 | 7.0 | 5.3–8.7 |
| No | 969 | 93.0 | 91.3–94.7 |
| **In the hospital or too sick to take HIV medicines** |  |  |  |
| Yes | 76 | 6.6 | 5.1–8.1 |
| No | 964 | 93.4 | 91.9–94.9 |
| \_ |  |  |  |
| ***Total*** | ***1,264*** | ***100*** |  |
| Abbreviation: CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Persons could report more than 1 reason for missed last dose. |

|  |
| --- |
| Table 9a. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by selected demographic characteristics—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Prescription of ARTa** | **ART dose adherenceb** | **Sustained viral suppressionc** | **Geometric mean CD4 count ≥200d** |
|  | **No.e** | **Row %f** | **95% CIg** | **No.e** | **Row %f** | **95% CIg** | **No.e** | **Row %f** | **95% CIg** | **No.e** | **Row %f** | **95% CIg** |
| **Gender** |  |  |  |  |  |  |  |  |  |  |  |  |
| Cisgender male | 836 | 83.0 | 80.2–85.7 | 521 | 57.7 | 54.2–61.1 | 615 | 61.5 | 58.2–64.8 | 724 | 91.9 | 90.1–93.8 |
| Cisgender female | 298 | 82.3 | 77.8–86.8 | 205 | 61.8 | 56.1–67.5 | 221 | 60.8 | 55.2–66.3 | 264 | 88.6 | 84.7–92.5 |
| Transgenderh | 22 | 93.1 | 82.8–100.0 | 12 | 49.4\* | 28.0–70.7 | 18 | 72.2\* | 51.5–92.9 | 20 | 91.4 | 79.9–100.0 |
| **Sexual orientation** |  |  |  |  |  |  |  |  |  |  |  |  |
| Lesbian or gay | 468 | 81.2 | 77.5–85.0 | 291 | 58.0 | 53.4–62.5 | 340 | 60.2 | 55.9–64.6 | 406 | 93.2 | 90.9–95.5 |
| Heterosexual or straight | 517 | 83.2 | 79.9–86.6 | 354 | 61.1 | 56.8–65.4 | 394 | 62.9 | 58.7–67.1 | 454 | 89.2 | 86.4–92.0 |
| Bisexual | 120 | 84.2 | 76.8–91.7 | 69 | 51.4 | 42.1–60.7 | 87 | 60.1 | 51.0–69.2 | 103 | 91.6 | 86.6–96.6 |
| Other | 38 | 97.5 | 92.6–100.0 | 19 | 50.2\* | 34.2–66.3 | 26 | 67.2 | 52.3–82.1 | 32 | 84.6 | 72.3–97.0 |
| **Race/ethnicity** |  |  |  |  |  |  |  |  |  |  |  |  |
| American Indian/Alaska Native | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asian | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Black/African American | 854 | 83.3 | 80.7–85.9 | 519 | 55.9 | 52.5–59.4 | 615 | 59.4 | 56.1–62.7 | 745 | 90.1 | 88.0–92.2 |
| Hispanic/Latinoi | 51 | 73.6 | 60.5–86.7 | 33 | 49.0 | 35.3–62.7 | 38 | 55.3 | 41.8–68.8 | 47 | 96.4 | 91.2–100.0 |
| Native Hawaiian/other Pacific Islander | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| White | 188 | 83.4 | 77.7–89.0 | 143 | 70.1 | 63.5–76.6 | 158 | 72.5 | 66.2–78.8 | 161 | 94.4 | 91.1–97.7 |
| Multiple races | 60 | 86.5 | 75.5–97.4 | 39 | 60.9 | 47.4–74.5 | 40 | 56.3 | 42.8–69.7 | 52 | 89.6 | 82.0–97.2 |
| **Age at time of interview (years)** |  |  |  |  |  |  |  |  |  |  |  |  |
| 18–29 | 118 | 77.0 | 69.1–85.0 | 54 | 42.7 | 33.4–52.0 | 63 | 41.6 | 33.1–50.0 | 109 | 93.5 | 89.3–97.7 |
| 30–39 | 240 | 82.4 | 77.2–87.6 | 130 | 48.9 | 42.4–55.4 | 155 | 53.7 | 47.4–59.9 | 204 | 88.0 | 83.8–92.2 |
| 40–49 | 251 | 83.6 | 78.9–88.3 | 153 | 56.2 | 49.8–62.5 | 184 | 60.7 | 54.6–66.7 | 217 | 91.0 | 87.3–94.7 |
| ≥50 | 549 | 84.5 | 81.2–87.7 | 401 | 67.4 | 63.5–71.4 | 453 | 70.6 | 66.7–74.4 | 480 | 92.1 | 89.7–94.4 |
| \_ |  |  |  |  |  |  |  |  |  |  |  |  |
| ***Total*** | ***1,158*** | ***83.0*** | ***80.7–85.3*** | ***738*** | ***58.4*** | ***55.5–61.4*** | ***855*** | ***61.5*** | ***58.7–64.3*** | ***1,010*** | ***91.1*** | ***89.4–92.8*** |
| Abbreviations: ART, antiretroviral therapy; CD4, CD4 T-lymphocyte count (cells/µL); CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Prescription of ART was based on documentation in the medical record in the 12 months before interview. |
| b During the 30 days before interview, 100% adherence to ART doses. |
| c Defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview. |
| d Geometric mean CD4 count was abstracted from medical records and based on the 12 months before interview. |
| e Numbers are unweighted. |
| f Percentages are weighted percentages. |
| g CIs incorporate weighted percentages. |
| h Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. |
| i Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category. |

|  |
| --- |
| Table 9b. Antiretroviral therapy (ART) prescription, ART dose adherence, sustained viral suppression, and geometric mean CD4 count among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Prescription of ARTa** | **ART dose adherenceb** | **Sustained viral suppressionc** | **Geometric mean CD4 count ≥200d** |
|  | **No.e** | **Row %f** | **95% CIg** | **No.e** | **Row %f** | **95% CIg** | **No.e** | **Row %f** | **95% CIg** | **No.e** | **Row %f** | **95% CIg** |
| **Cycle year** |  |  |  |  |  |  |  |  |  |  |  |  |
| 2015 | 140 | 84.9 | 79.0–90.9 | 85 | 57.8 | 49.0–66.6 | 90 | 53.8 | 45.5–62.0 | 120 | 90.9 | 86.0–95.9 |
| 2016 | 177 | 83.7 | 77.6–89.7 | 105 | 57.8 | 50.0–65.6 | 138 | 65.3 | 57.9–72.6 | 145 | 85.0 | 79.2–90.8 |
| 2017 | 179 | 85.1 | 80.1–90.0 | 119 | 60.6 | 53.6–67.5 | 128 | 61.4 | 54.6–68.1 | 157 | 89.8 | 85.3–94.4 |
| 2018 | 147 | 79.9 | 72.7–87.1 | 100 | 58.0 | 49.6–66.4 | 114 | 63.7 | 55.6–71.8 | 134 | 94.0 | 90.2–97.8 |
| 2019 | 184 | 78.3 | 70.9–85.7 | 110 | 57.6 | 49.9–65.2 | 134 | 55.9 | 48.2–63.6 | 160 | 89.0 | 84.0–93.9 |
| 2020 | 168 | 82.7 | 77.1–88.2 | 109 | 58.3 | 50.9–65.6 | 119 | 60.2 | 53.2–67.2 | 146 | 92.5 | 88.4–96.6 |
| 2021 | 163 | 86.5 | 81.5–91.5 | 110 | 58.9 | 51.4–66.3 | 132 | 69.1 | 62.3–75.9 | 148 | 95.7 | 92.4–98.9 |
| \_ |  |  |  |  |  |  |  |  |  |  |  |  |
| ***Total*** | ***1,158*** | ***83.0*** | ***80.7–85.3*** | ***738*** | ***58.4*** | ***55.5–61.4*** | ***855*** | ***61.5*** | ***58.7–64.3*** | ***1,010*** | ***91.1*** | ***89.4–92.8*** |
| Abbreviations: ART, antiretroviral therapy; CD4, CD4 T-lymphocyte count (cells/µL); CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Prescription of ART was based on documentation in the medical record in the 12 months before interview. |
| b During the 30 days before interview, 100% adherence to ART doses. |
| c Defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview. |
| d Geometric mean CD4 count was abstracted from medical records and based on the 12 months before interview. |
| e Numbers are unweighted. |
| f Percentages are weighted percentages. |
| g CIs incorporate weighted percentages. |

|  |
| --- |
| Table 10. Symptoms of depression and generalized anxiety disorder during the 2 weeks before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Symptoms of depression, based on DSM-IV criteriad** |  |  |  |
| No depression | 1,114 | 83.2 | 81.0–85.3 |
| Major depression | 115 | 8.7 | 7.1–10.3 |
| Other depression | 116 | 8.2 | 6.7–9.7 |
| **Symptoms of moderate or severe depression (PHQ-8 score ≥10)** |  |  |  |
| Yes | 185 | 13.7 | 11.8–15.7 |
| No | 1,161 | 86.3 | 84.3–88.2 |
| **Symptoms of generalized anxiety disordere** |  |  |  |
| No anxiety | 1,047 | 77.6 | 75.2–80.0 |
| Mild anxiety | 78 | 6.0 | 4.6–7.4 |
| Moderate anxiety | 113 | 8.2 | 6.7–9.8 |
| Severe anxiety | 109 | 8.2 | 6.6–9.8 |
| \_ |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviations: CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GAD-7, Generalized Anxiety Disorder 7-item Scale [footnotes only]; PHQ-8, Patient Health Questionnaire. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Responses to the items on PHQ-8 were used to define “major depression” and “other depression” according to criteria from the DSM-IV. To meet the criteria for major depression, a participant must have experienced 5 or more symptoms at least “more than half the days,” and one of the symptoms must be anhedonia or feelings of hopelessness. For other depression, a participant must have experienced 2 to 4 symptoms at least “more than half the days,” and one of the symptoms must be anhedonia or feelings of hopelessness. |
| e Responses to the GAD–7 were used to define “mild anxiety,” “moderate anxiety,” and “severe anxiety” according to criteria from the DSM-IV. “Severe anxiety” was defined as having a score of ≥15; “moderate anxiety” was defined as having a score of 10–14; and “mild anxiety” was defined as having a score of 5–9. |

|  |
| --- |
| Table 11. Tobacco and electronic cigarette or other vaping device use among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Smoked ≥100 cigarettes (lifetime)** |  |  |  |
| No | 699 | 51.5 | 48.6–54.4 |
| Yes | 646 | 48.5 | 45.6–51.4 |
| **Cigarette smoking status** |  |  |  |
| Current smoker | 415 | 30.9 | 28.3–33.6 |
| Former smoker | 231 | 17.6 | 15.4–19.8 |
| Never smoked | 699 | 51.5 | 48.6–54.4 |
| **Frequency of current cigarette smoking** |  |  |  |
| Daily | 339 | 25.1 | 22.6–27.6 |
| Weekly | 35 | 2.9 | 1.8–3.9 |
| Monthly | -- | -- | -- |
| Less than monthly | 29 | 2.2 | 1.4–3.0 |
| Never | 930 | 69.1 | 66.4–71.7 |
| **Smoked ≥50 cigars, cigarillos, or little filtered cigars (lifetime)** |  |  |  |
| Yes | 243 | 18.1 | 15.9–20.4 |
| No | 1,104 | 81.9 | 79.6–84.1 |
| **Cigars, cigarillos, or little filtered cigars smoking status** |  |  |  |
| Current smoker | 134 | 9.9 | 8.2–11.6 |
| Former smoker | 109 | 8.2 | 6.6–9.8 |
| Never smoked | 1,104 | 81.9 | 79.6–84.1 |
| **Frequency of current cigars, cigarillos, or little filtered cigars smoking** |  |  |  |
| Daily | 35 | 2.7 | 1.8–3.7 |
| Some days | 46 | 3.4 | 2.3–4.4 |
| Rarely | 53 | 3.8 | 2.8–4.9 |
| Never | 1,213 | 90.1 | 88.4–91.8 |
| **Electronic cigarette (2015-2020)** |  |  |  |
| Used in the past 30 days | 75 | 6.5 | 5.0–8.1 |
| Used, but not in the past 30 days | 253 | 22.1 | 19.5–24.7 |
| Never used | 829 | 71.3 | 68.5–74.2 |
| **Electronic cigarette or other vaping device smoking status (2021)d** |  |  |  |
| Used in the past 30 days | 26 | 14.2 | 9.0–19.4 |
| Used, but not in the past 30 days | 28 | 15.4 | 10.0–20.8 |
| Never used | 136 | 70.4 | 63.7–77.2 |
| \_ |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviation: CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Includes nicotine, tobacco, marijuana, flavoring, or any other substances. |

|  |
| --- |
| Table 12. Alcohol use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Any alcohol used** |  |  |  |
| Yes | 893 | 67.3 | 64.7–70.0 |
| No | 454 | 32.7 | 30.0–35.3 |
| **Frequency of alcohol use** |  |  |  |
| Daily | 87 | 6.7 | 5.2–8.1 |
| Weekly | 279 | 21.1 | 18.8–23.4 |
| Monthly | 162 | 11.8 | 10.0–13.7 |
| Less than monthly | 365 | 27.8 | 25.2–30.3 |
| Never | 454 | 32.7 | 30.0–35.3 |
| **Binge drinking, past 30 dayse** |  |  |  |
| Yes | 202 | 15.7 | 13.6–17.9 |
| No | 1,139 | 84.3 | 82.1–86.4 |
| \_ |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviation: CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Persons who drank ≥1 alcoholic beverage during the 12 months before interview. Alcoholic beverage was defined as a 12-ounce beer, 5-ounce glass of wine, or 1.5-ounce shot of liquor. |
| e Persons who drank ≥5 alcoholic beverages in a single sitting (≥4 for women) during the 30 days before interview. |

|  |
| --- |
| Table 13. Noninjection drug use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Use of any noninjection drugsd** |  |  |  |
| Yes | 462 | 35.0 | 32.3–37.7 |
| No | 884 | 65.0 | 62.3–67.7 |
|  |  |  |  |
| **Noninjection drugs usedd** |  |  |  |
|  |  |  |  |
| **Marijuanae** |  |  |  |
| Yes | 410 | 31.0 | 28.3–33.6 |
| No | 935 | 69.0 | 66.4–71.7 |
| **Amyl nitrite (poppers)** |  |  |  |
| Yes | 100 | 8.3 | 6.7–10.0 |
| No | 1,246 | 91.7 | 90.0–93.3 |
| **Cocaine that is smoked or snorted** |  |  |  |
| Yes | 77 | 5.7 | 4.4–7.0 |
| No | 1,269 | 94.3 | 93.0–95.6 |
| **Methamphetamine (e.g., crystal meth, tina, crank, ice)** |  |  |  |
| Yes | 52 | 4.2 | 3.1–5.4 |
| No | 1,294 | 95.8 | 94.6–96.9 |
| **Prescription opioids (e.g., oxycodone, hydrocodone, Vicodin, Percocet)f** |  |  |  |
| Yes | 45 | 3.2 | 2.2–4.2 |
| No | 1,301 | 96.8 | 95.8–97.8 |
| **Club drugs (e.g., Ecstasy or X, ketamine or Special K, GHB or Liquid Ecstasy)** |  |  |  |
| Yes | 36 | 2.9 | 1.9–3.9 |
| No | 1,310 | 97.1 | 96.1–98.1 |
| **Prescription tranquilizers (e.g., Valium, Ativan, Xanax, downers, nerve pills)f** |  |  |  |
| Yes | 40 | 2.8 | 1.9–3.7 |
| No | 1,306 | 97.2 | 96.3–98.1 |
| **Crack** |  |  |  |
| Yes | 37 | 2.5 | 1.6–3.3 |
| No | 1,309 | 97.5 | 96.7–98.4 |
| **Heroin or opium that is smoked or snorted** |  |  |  |
| Yes | -- | -- | -- |
| No | 1,176 | 99.7 | 99.3–100.0 |
| \_ |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Disclaimer: The use of trade names is for identification only and does not imply endorsement by the Department of Health and Human Services, the Centers for Disease Control and Prevention, or the Georgia Department of Public Health. |
| Abbreviations: CI, confidence interval; GHB, gamma hydroxybutyrate. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| Persons could report taking >1 noninjection drug. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Includes all drugs that were not injected (i.e., administered by any route other than injection), including legal drugs that were not used for medical purposes. |
| e Includes vaping marijuana for 2021. |
| f Not prescribed or prescribed but taken more than directed. |
|  |

|  |
| --- |
| Table 14. Injection drug use during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Use of any injection drugs** |  |  |  |
| Yes | 18 | 1.6 | 0.8–2.4 |
| No | 1,328 | 98.4 | 97.6–99.2 |
|  |  |  |  |
| **Injection drugs used** |  |  |  |
|  |  |  |  |
| **Methamphetamine (e.g., crystal meth, tina, crank, ice)** |  |  |  |
| Yes | 16 | 1.5 | 0.7–2.2 |
| No | 1,330 | 98.5 | 97.8–99.3 |
| **Heroin** |  |  |  |
| Yes | -- | -- | -- |
| No | 1,342 | 99.7 | 99.4–100.0 |
| **Cocaine** |  |  |  |
| Yes | -- | -- | -- |
| No | 1,342 | 99.7 | 99.5–100.0 |
| **Prescription opioids (e.g., OxyContin, oxycodone, hydrocodone)** |  |  |  |
| Yes | -- | -- | -- |
| No | 1,344 | 99.9 | 99.7–100.0 |
| **Heroin and cocaine (speedball)** |  |  |  |
| Yes | -- | -- | -- |
| No | 1,345 | 99.9 | 99.8–100.0 |
| \_ |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Disclaimer: The use of trade names is for identification only and does not imply endorsement by the Department of Health and Human Services, the Centers for Disease Control and Prevention, or the Georgia Department of Public Health. |
| Abbreviation: CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| Persons could report taking >1 injection drug. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |

|  |
| --- |
| Table 15. Receipt of Papanicolaou testing and pregnancy since HIV diagnosis among cisgender women with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Papanicolaou (Pap) test, past 3 yearsd** |  |  |  |
| Yes | 169 | 87.4 | 82.6–92.3 |
| No | 25 | 12.6 | 7.7–17.4 |
| **Pregnant since HIV diagnosis** |  |  |  |
| Yes | 93 | 28.7 | 23.5–34.0 |
| No | 251 | 71.3 | 66.0–76.5 |
| \_ |  |  |  |
| ***Total*** | ***356*** | ***100*** |  |
| Abbreviation: CI, confidence interval. |
| *Note.* Measures are self-reported. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Or since HIV diagnosis for women with a diagnosis within the past 3 years. |

|  |
| --- |
| Table 16. Sexual behavior during the 12 months before interview among cisgender men and cisgender women with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Cisgender men** | **Cisgender women** |
|  | **No.a** | **%b** | **95% CIc** | **No.a** | **%b** | **95% CIc** |
| **Behavior** |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **Engaged in vaginal or anal sex** |  |  |  |  |  |  |
| Yes | 665 | 70.1 | 67.0–73.2 | 191 | 57.0 | 51.4–62.6 |
| No | 292 | 29.9 | 26.8–33.0 | 154 | 43.0 | 37.4–48.6 |
| **Engaged in vaginal sex** |  |  |  |  |  |  |
| Yes | 189 | 19.4 | 16.7–22.0 | 190 | 56.5 | 50.8–62.1 |
| No | 769 | 80.6 | 78.0–83.3 | 155 | 43.5 | 37.9–49.2 |
| **Engaged in anal sex with cisgender men** |  |  |  |  |  |  |
| Yes | 501 | 51.8 | 48.5–55.2 | -- | -- | -- |
| No | 481 | 48.2 | 44.8–51.5 | 332 | 96.3 | 94.0–98.5 |
| **Engaged in anal sex with cisgender women** |  |  |  |  |  |  |
| Yes | 15 | 1.5 | 0.6–2.3 | N/A | N/A | N/A |
| No | 968 | 98.5 | 97.7–99.4 | N/A | N/A | N/A |
|  |  |  |  |  |  |  |
| **Number of vaginal or anal sex partners among sexually active persons** |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **MSMd** |  |  |  |  |  |  |
| Mean | 5 |  |  | N/A |  |  |
| Median | 2 |  |  | N/A |  |  |
| Range | 1–120 |  |  | N/A |  |  |
| **MSWe** |  |  |  |  |  |  |
| Mean | 2 |  |  | N/A |  |  |
| Median | 1 |  |  | N/A |  |  |
| Range | 1–25 |  |  | N/A |  |  |
| **WSMf** |  |  |  |  |  |  |
| Mean | N/A |  |  | 1 |  |  |
| Median | N/A |  |  | 1 |  |  |
| Range | N/A |  |  | 1–10 |  |  |
| \_ |  |  |  |  |  |  |
| ***Total*** | ***987*** | ***100*** |  | ***356*** | ***100*** |  |
| Abbreviations: CI, confidence interval; N/A, not applicable; MSM, cisgender men who had sex with cisgender men; MSW, cisgender men who had sex only with cisgender women; WSM, cisgender women who had sex with cisgender men. |
| *Note*. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Cisgender men who had anal sex with cisgender men in the 12 months before interview. |
| e Cisgender men who had vaginal or anal sex only with cisgender women in the 12 months before interview. |
| f Cisgender women who had vaginal or anal sex with cisgender men in the 12 months before interview. |

|  |
| --- |
| Table 17. Sexual behavior during the 12 months before interview among cisgender men who had sex with cisgender men (MSM), cisgender men who had sex only with cisgender women (MSW), and cisgender women who had sex with cisgender men (WSM), with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **MSM** | **MSW** | **WSM** |
|  | **No.a** | **col %b** | **95% CIc** | **No.a** | **col %b** | **95% CIc** | **No.a** | **col %b** | **95% CIc** |
| **Engaged in any sex without using an HIV prevention strategy, among all personsd** |  |  |  |  |  |  |  |  |  |
| Yes | 53 | 7.4 | 5.4–9.5 | 15 | 6.7 | 3.2–10.3 | 27 | 9.0 | 5.5–12.5 |
| No | 632 | 92.6 | 90.5–94.6 | 253 | 93.3 | 89.7–96.8 | 314 | 91.0 | 87.5–94.5 |
| **Engaged in any sex without using an HIV prevention strategy, among sexually active personsd** |  |  |  |  |  |  |  |  |  |
| Yes | 53 | 10.2 | 7.5–13.0 | 15 | 10.8 | 5.2–16.3 | 27 | 15.8 | 9.9–21.6 |
| No | 447 | 89.8 | 87.0–92.5 | 146 | 89.2 | 83.7–94.8 | 164 | 84.2 | 78.4–90.1 |
|  |  |  |  |  |  |  |  |  |  |
| **Percentages of sexually active persons who used an HIV prevention strategy with at least 1 partner** |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| **Sex while having sustained viral suppressione** |  |  |  |  |  |  |  |  |  |
| Yes | 302 | 60.2 | 55.6–64.8 | 101 | 60.9 | 52.8–69.0 | 115 | 57.5 | 49.8–65.2 |
| No | 200 | 39.8 | 35.2–44.4 | 61 | 39.1 | 31.0–47.2 | 76 | 42.5 | 34.8–50.2 |
| **Condom-protected sexf** |  |  |  |  |  |  |  |  |  |
| Yes | 35 | 47.8 | 36.1–59.6 | 15 | 64.6\* | 44.6–84.5 | 11 | 42.6\* | 23.2–62.0 |
| No | 39 | 52.2 | 40.4–63.9 | 8 | 35.4\* | 15.5–55.4 | 14 | 57.4\* | 38.0–76.8 |
| **Condomless sex with a partner on PrEPg** |  |  |  |  |  |  |  |  |  |
| Yes | 64 | 13.0 | 9.9–16.1 | -- | -- | -- | -- | -- | -- |
| No | 436 | 87.0 | 83.9–90.1 | 160 | 98.8 | 97.1–100.0 | 187 | 97.5 | 94.9–100.0 |
| **Sex with a partner with HIVh** |  |  |  |  |  |  |  |  |  |
| Yes | 338 | 66.3 | 61.8–70.8 | 48 | 27.6 | 20.6–34.6 | 54 | 28.5 | 21.4–35.6 |
| No | 164 | 33.7 | 29.2–38.2 | 114 | 72.4 | 65.4–79.4 | 137 | 71.5 | 64.4–78.6 |
| \_ |  |  |  |  |  |  |  |  |  |
| ***Total*** | ***697*** | ***100*** |  | ***271*** | ***100*** |  | ***345*** | ***100*** |  |
| Abbreviations: CI, confidence interval; MSM, cisgender men who had sex with cisgender men; MSW, cisgender men who had sex only with cisgender women; WSM, cisgender women who had sex with cisgender men; PrEP, preexposure prophylaxis. |
| *Note*. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Persons who reported no anal, vaginal, or oral sex in the 12 months before interview were categorized according to self-reported sexual orientation. This table does not include information on cisgender women who had sex with cisgender women only, cisgender women who had sex with transgender persons only, or cisgender men who had sex with transgender persons only. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Vaginal or anal sex with at least 1 partner with an HIV-negative or unknown status while not having sustained viral suppression (defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview), a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the 5 most recent sex partners. |
| e Defined as having all HIV viral loads being undetectable or <200 copies/mL, as documented in the medical record in the past 12 months before interview. |
| f Condoms were consistently used with at least 1 vaginal or anal sex partner. |
| g At least 1 condomless-sex partner without HIV was on PrEP. PrEP use was only measured among the 5 most recent partners and was reported by the partner with HIV. |
| h Sex with at least 1 partner with HIV. |

|  |
| --- |
| Table 18. Met and unmet needs for HIV ancillary services during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Among all persons with diagnosed HIV** | **Among persons with diagnosed HIV who had a need for the service** |
|  | *Received services* | *Need, did not receive services* | *Need, did not receive services* |
|  | **No.a** | **col %b** | **95% CIc** | **No.a** | **col %b** | **95% CIc** | **No.a** | **col %b** | **95% CIc** |
| **HIV support services** |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| **HIV case management services** |  |  |  |  |  |  |  |  |  |
| Yes | 628 | 45.0 | 42.1–47.8 | 132 | 10.0 | 8.2–11.7 | 132 | 18.1 | 15.1–21.2 |
| No | 716 | 55.0 | 52.2–57.9 | 1,212 | 90.0 | 88.3–91.8 | 628 | 81.9 | 78.8–84.9 |
| **Medicine through ADAP** |  |  |  |  |  |  |  |  |  |
| Yes | 613 | 43.4 | 40.5–46.2 | 52 | 4.3 | 3.1–5.6 | 52 | 9.1 | 6.6–11.7 |
| No | 718 | 56.6 | 53.8–59.5 | 1,279 | 95.7 | 94.4–96.9 | 613 | 90.9 | 88.3–93.4 |
| **Professional help remembering to take HIV medicines on time or correctly (adherence support services)** |  |  |  |  |  |  |  |  |  |
| Yes | 475 | 33.5 | 30.8–36.2 | -- | -- | -- | -- | -- | -- |
| No | 868 | 66.5 | 63.8–69.2 | 1,335 | 99.5 | 99.1–99.8 | 475 | 98.4 | 97.3–99.5 |
| **Patient navigation services** |  |  |  |  |  |  |  |  |  |
| Yes | 166 | 11.1 | 9.4–12.8 | 65 | 4.8 | 3.5–6.0 | 65 | 30.0 | 23.5–36.4 |
| No | 1,177 | 88.9 | 87.2–90.6 | 1,278 | 95.2 | 94.0–96.5 | 166 | 70.0 | 63.6–76.5 |
| **HIV peer group support** |  |  |  |  |  |  |  |  |  |
| Yes | 153 | 10.4 | 8.7–12.1 | 107 | 7.5 | 6.0–9.0 | 107 | 41.8 | 35.4–48.2 |
| No | 1,190 | 89.6 | 87.9–91.3 | 1,236 | 92.5 | 91.0–94.0 | 153 | 58.2 | 51.8–64.6 |
|  |  |  |  |  |  |  |  |  |  |
| **Non-HIV medical services** |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| **Dental care** |  |  |  |  |  |  |  |  |  |
| Yes | 665 | 49.4 | 46.5–52.3 | 422 | 30.9 | 28.3–33.5 | 422 | 38.5 | 35.4–41.6 |
| No | 682 | 50.6 | 47.7–53.5 | 925 | 69.1 | 66.5–71.7 | 665 | 61.5 | 58.4–64.6 |
| **Mental health services** |  |  |  |  |  |  |  |  |  |
| Yes | 339 | 24.8 | 22.3–27.3 | 140 | 10.2 | 8.5–11.9 | 140 | 29.2 | 24.8–33.5 |
| No | 1,006 | 75.2 | 72.7–77.7 | 1,205 | 89.8 | 88.1–91.5 | 339 | 70.8 | 66.5–75.2 |
| **Drug or alcohol counseling or treatment** |  |  |  |  |  |  |  |  |  |
| Yes | 65 | 4.7 | 3.5–5.9 | 33 | 2.4 | 1.6–3.3 | 33 | 34.2 | 24.3–44.1 |
| No | 1,282 | 95.3 | 94.1–96.5 | 1,314 | 97.6 | 96.7–98.4 | 65 | 65.8 | 55.9–75.7 |
| **Domestic violence services** |  |  |  |  |  |  |  |  |  |
| Yes | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| No | 1,334 | 98.8 | 98.0–99.5 | 1,340 | 99.4 | 99.0–99.8 | 14 | 68.3\* | 47.5–89.0 |
|  |  |  |  |  |  |  |  |  |  |
| **Subsistence services** |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| **SNAP or WIC** |  |  |  |  |  |  |  |  |  |
| Yes | 549 | 39.8 | 37.0–42.6 | 198 | 14.7 | 12.7–16.7 | 198 | 27.0 | 23.5–30.4 |
| No | 799 | 60.2 | 57.4–63.0 | 1,150 | 85.3 | 83.3–87.3 | 549 | 73.0 | 69.6–76.5 |
| **Transportation assistance** |  |  |  |  |  |  |  |  |  |
| Yes | 253 | 17.9 | 15.7–20.1 | 132 | 9.5 | 7.8–11.2 | 132 | 34.7 | 29.6–39.9 |
| No | 1,094 | 82.1 | 79.9–84.3 | 1,215 | 90.5 | 88.8–92.2 | 253 | 65.3 | 60.1–70.4 |
| **Meal or food servicesd** |  |  |  |  |  |  |  |  |  |
| Yes | 233 | 16.3 | 14.3–18.3 | 148 | 10.9 | 9.1–12.6 | 148 | 40.0 | 34.7–45.2 |
| No | 1,115 | 83.7 | 81.7–85.7 | 1,200 | 89.1 | 87.4–90.9 | 233 | 60.0 | 54.8–65.3 |
| **Shelter or housing services** |  |  |  |  |  |  |  |  |  |
| Yes | 118 | 8.1 | 6.6–9.6 | 203 | 14.5 | 12.5–16.4 | 203 | 64.1 | 58.6–69.6 |
| No | 1,229 | 91.9 | 90.4–93.4 | 1,144 | 85.5 | 83.6–87.5 | 118 | 35.9 | 30.4–41.4 |
| \_ |  |  |  |  |  |  |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  | ***1,369*** | ***100*** |  | ***1,369*** | ***100*** |  |
| Abbreviations: CI, confidence interval; ADAP, AIDS Drug Assistance Program; SNAP, Supplemental Nutrition Assistance Program; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children. |
| *Note.* Persons could report receiving or needing more than 1 service. Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Includes services such as soup kitchens, food pantries, food banks, church dinners, or food delivery services. |

|  |
| --- |
| Table 19. Prevalence of physical violence by an intimate partner and forced sex among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Was ever slapped, punched, shoved, kicked, choked, or otherwise physically hurt by a romantic or sexual partner** |  |  |  |
| Yes | 343 | 25.8 | 23.2–28.3 |
| No | 994 | 74.2 | 71.7–76.8 |
| **Was slapped, punched, shoved, kicked, choked, or otherwise physically hurt by a romantic or sexual partner, past 12 months** |  |  |  |
| Yes | 52 | 3.9 | 2.8–5.0 |
| No | 1,284 | 96.1 | 95.0–97.2 |
| **Was ever threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex** |  |  |  |
| Yes | 212 | 16.6 | 14.4–18.8 |
| No | 1,127 | 83.4 | 81.2–85.6 |
| **Was threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex, past 12 months** |  |  |  |
| Yes | -- | -- | -- |
| No | 1,327 | 99.2 | 98.7–99.7 |
| \_ |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviation: CI, confidence interval. |
| *Note.* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |

|  |
| --- |
| Table 20. Prevention services received during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **%b** | **95% CIc** |
| **Talked to a physician, nurse, or other health care worker about how to prevent HIV or other STDs** |  |  |  |
| Yes | 743 | 55.1 | 52.2–57.9 |
| No | 606 | 44.9 | 42.1–47.8 |
| **Talked to an outreach worker, counselor, or prevention program worker about how to prevent HIV or other STDs** |  |  |  |
| Yes | 377 | 27.0 | 24.5–29.5 |
| No | 972 | 73.0 | 70.5–75.5 |
| **Received free condoms, not counting those given by a friend, relative, or sex partner** |  |  |  |
| Yes | 640 | 47.2 | 44.4–50.1 |
| No | 711 | 52.8 | 49.9–55.6 |
| \_ |  |  |  |
| ***Total*** | ***1,369*** | ***100*** |  |
| Abbreviation: CI, confidence interval. |
| *Note.* Persons could report receiving more than 1 prevention service. |
| Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |

|  |
| --- |
| Table 21a. National HIV/AIDS Strategy indicators: Self-rated health and unmet needs for mental health services during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Good or better self-rated healtha** | **Unmet needs for mental health services among persons who needed mental health servicesb** |
|  | **No.c** | **Row %d** | **95% CIe** | **No.c** | **Row %d** | **95% CIe** |
| **Gender** |  |  |  |  |  |  |
| Cisgender male | 421 | 73.5 | 69.5–77.5 | 54 | 28.1 | 21.3–34.9 |
| Cisgender female | 123 | 62.0 | 54.8–69.2 | 25 | 33.2 | 22.0–44.4 |
| Transgenderf | 13 | 86.2\* | 70.2–100.0 | -- | -- | -- |
| **Sexual orientation** |  |  |  |  |  |  |
| Lesbian or gay | 270 | 78.0 | 73.2–82.9 | 32 | 27.4 | 18.6–36.2 |
| Heterosexual or straight | 204 | 61.0 | 55.4–66.7 | 32 | 30.3 | 21.2–39.4 |
| Bisexual | 61 | 77.6 | 67.6–87.6 | 11 | 27.4\* | 12.2–42.5 |
| Other | 19 | 70.1\* | 52.4–87.7 | -- | -- | -- |
| **Race/ethnicity** |  |  |  |  |  |  |
| American Indian/Alaska Native | -- | -- | -- | 0 | 0 | N/A |
| Asian | -- | -- | -- | 0 | 0 | N/A |
| Black/African American | 419 | 71.0 | 67.0–74.9 | 62 | 33.0 | 25.9–40.2 |
| Hispanic/Latinog | 28 | 73.8 | 59.4–88.1 | -- | -- | -- |
| Native Hawaiian/other Pacific Islander | 0 | 0 | N/A | 0 | 0 | N/A |
| White | 88 | 75.8 | 67.4–84.3 | 11 | 24.3 | 11.5–37.2 |
| Multiple races | 21 | 52.1\* | 34.8–69.5 | -- | -- | -- |
| **Age at time of interview (years)** |  |  |  |  |  |  |
| 18–29 | 75 | 85.6 | 78.1–93.0 | 13 | 38.1\* | 19.1–57.2 |
| 30–39 | 132 | 77.2 | 70.1–84.3 | 24 | 44.1 | 30.3–57.8 |
| 40–49 | 109 | 64.8 | 56.8–72.8 | 12 | 19.5 | 8.8–30.1 |
| ≥50 | 242 | 67.3 | 62.2–72.5 | 32 | 25.1 | 17.3–33.0 |
| **National HIV/AIDS Strategy priority populationsh** |  |  |  |  |  |  |
| All MSMi | 332 | 78.6 | 74.2–82.9 | 42 | 28.3 | 20.4–36.1 |
| Black/African American MSMi | 232 | 80.6 | 75.6–85.7 | 29 | 30.8 | 20.6–41.1 |
| Hispanic/Latino MSMg,i | 19 | 74.7\* | 56.0–93.3 | -- | -- | -- |
| American Indian/Alaska Native MSMi | -- | -- | -- | 0 | 0 | N/A |
| Persons aged 18-24 yearsj | 24 | 95.7\* | 87.4–100.0 | 5 | 62.7\* | 28.0–97.5 |
| People who inject drugsk | -- | -- | -- | -- | -- | -- |
| Black/African American cisgender women | 100 | 60.8 | 52.9–68.7 | 21 | 40.0 | 26.3–53.6 |
| Transgender womenl | 13 | 86.2\* | 70.2–100.0 | -- | -- | -- |
| \_ |  |  |  |  |  |  |
| ***Total*** | ***558*** | ***71.0*** | ***67.6–74.5*** | ***81*** | ***29.1*** | ***23.4–34.9*** |
| Abbreviations: CI, confidence interval; MSM, men who have sex with men. |
| *Note:* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a “Good or better self-rated health” defined as rating one’s health as good, very good, or excellent (as opposed to poor or fair) at the time of interview. |
| b “Unmet need for mental health services from a mental health professional” defined as needing, but not receiving, services from a mental health professional among those who indicated needing mental health services (i.e., receiving or needing but not receiving) during the past 12 months. |
| c Numbers are unweighted. |
| d Percentages are weighted percentages. |
| e CIs incorporate weighted percentages. |
| f Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. |
| g Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category. |
| h The National HIV/AIDS Strategy defines priority populations as populations that are disproportionately affected by HIV, and recommends that public health resources be delivered to priority populations for the greatest public health impact. For more information: https://www.hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025/ |
| i Cisgender men who had anal sex with cisgender men in the 12 months before interview. |
| j Priority population for youths includes persons aged 13-24 years; however, data from MMP are only available and presented for persons aged 18-24 years. |
| k Defined as people who injected drugs in the past 12 months. |
| l Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender. |

|  |
| --- |
| Table 21b. National HIV/AIDS Strategy indicators: Self-rated health and unmet needs for mental health services during the 12 months before interview among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Good or better self-rated healtha** | **Unmet needs for mental health services among persons who needed mental health servicesb** |
|  | **No.c** | **Row %d** | **95% CIe** | **No.c** | **Row %d** | **95% CIe** |
| **Cycle year** |  |  |  |  |  |  |
| 2015 | N/A | N/A | N/A | 22 | 27.9 | 16.9–39.0 |
| 2016 | N/A | N/A | N/A | 16 | 26.0 | 14.4–37.6 |
| 2017 | N/A | N/A | N/A | 21 | 34.6 | 22.4–46.8 |
| 2018 | 132 | 76.0 | 68.9–83.1 | 12 | 18.8 | 8.2–29.4 |
| 2019 | 153 | 66.9 | 59.4–74.4 | 27 | 30.4 | 19.7–41.1 |
| 2020 | 147 | 72.9 | 66.5–79.3 | 19 | 32.2 | 19.8–44.6 |
| 2021 | 126 | 68.6 | 62.0–75.3 | 23 | 33.5 | 22.1–44.8 |
| Abbreviations: CI, confidence interval. |
| *Note:* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a “Good or better self-rated health” defined as rating one’s health as good, very good, or excellent (as opposed to poor or fair) at the time of interview. |
| b “Unmet need for mental health services from a mental health professional” defined as needing, but not receiving, services from a mental health professional among those who indicated needing mental health services (i.e., receiving or needing but not receiving) during the past 12 months. |
| c Numbers are unweighted. |
| d Percentages are weighted percentages. |
| e CIs incorporate weighted percentages. |

|  |
| --- |
| Table 22a. National HIV/AIDS Strategy indicators: Unstable housing or homelessness, unemployment, and hunger/food insecurity during the 12 months before interview among persons with diagnosed HIV, overall and by demographic characteristics—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Unstable housing or homelessnessa** | **Unemploymentb** | **Hunger/Food insecurityc** |
|  | **No.d** | **Row %e** | **95% CIf** | **No.d** | **Row %e** | **95% CIf** | **No.d** | **Row %e** | **95% CIf** |
| **Gender** |  |  |  |  |  |  |  |  |  |
| Cisgender male | 129 | 21.4 | 17.8–24.9 | 156 | 15.1 | 12.8–17.4 | 177 | 18.4 | 15.8–21.0 |
| Cisgender female | 49 | 23.8 | 17.5–30.1 | 48 | 14.3 | 10.3–18.3 | 60 | 15.5 | 11.6–19.4 |
| Transgenderg | 8 | 54.0\* | 27.9–80.0 | -- | -- | -- | 9 | 40.0\* | 18.6–61.3 |
| **Sexual orientation** |  |  |  |  |  |  |  |  |  |
| Lesbian or gay | 69 | 18.7 | 14.4–23.0 | 92 | 15.7 | 12.6–18.8 | 93 | 17.3 | 13.9–20.7 |
| Heterosexual or straight | 80 | 23.6 | 18.7–28.4 | 92 | 15.1 | 12.1–18.2 | 106 | 16.9 | 13.7–20.0 |
| Bisexual | 23 | 26.6 | 16.3–36.9 | 15 | 9.4 | 4.7–14.2 | 31 | 21.1 | 13.9–28.3 |
| Other | 11 | 40.3\* | 21.3–59.3 | -- | -- | -- | 14 | 35.7\* | 20.5–50.9 |
| **Race/ethnicity** |  |  |  |  |  |  |  |  |  |
| American Indian/Alaska Native | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asian | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A |
| Black/African American | 147 | 24.6 | 20.9–28.3 | 172 | 17.1 | 14.7–19.6 | 186 | 19.0 | 16.4–21.6 |
| Hispanic/Latinoh | 10 | 23.9 | 10.0–37.7 | -- | -- | -- | -- | -- | -- |
| Native Hawaiian/other Pacific Islander | 0 | 0 | N/A | -- | -- | -- | 0 | 0 | N/A |
| White | -- | -- | -- | 18 | 7.9 | 4.2–11.5 | 30 | 13.3 | 8.4–18.2 |
| Multiple races | 17 | 39.0\* | 22.6–55.4 | -- | -- | -- | 18 | 26.9 | 14.9–38.8 |
| **Age at time of interview (years)** |  |  |  |  |  |  |  |  |  |
| 18–29 | 42 | 45.7 | 34.4–56.9 | 43 | 30.6 | 22.6–38.5 | 36 | 26.0 | 18.3–33.7 |
| 30–39 | 56 | 31.3 | 23.9–38.6 | 54 | 17.9 | 13.3–22.6 | 68 | 23.0 | 17.8–28.1 |
| 40–49 | 38 | 21.7 | 15.1–28.3 | 44 | 14.9 | 10.6–19.1 | 53 | 17.6 | 13.0–22.3 |
| ≥50 | 50 | 12.9 | 9.3–16.5 | 66 | 9.5 | 7.2–11.7 | 89 | 13.9 | 11.0–16.8 |
| **National HIV/AIDS Strategy priority populationsi** |  |  |  |  |  |  |  |  |  |
| All MSMj | 92 | 20.6 | 16.5–24.6 | 103 | 14.0 | 11.4–16.7 | 121 | 17.9 | 14.8–21.0 |
| Black/African American MSMj | 72 | 24.8 | 19.5–30.2 | 80 | 17.3 | 13.7–20.9 | 91 | 21.3 | 17.2–25.3 |
| Hispanic/Latino MSMh,j | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| American Indian/Alaska Native MSMj | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Persons aged 18-24 yearsk | 14 | 56.5\* | 35.9–77.0 | 12 | 36.3\* | 19.7–53.0 | 11 | 32.7\* | 16.4–49.1 |
| People who inject drugsl | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Black/African American cisgender women | 38 | 22.4 | 15.6–29.2 | 42 | 14.8 | 10.3–19.3 | 44 | 14.0 | 9.9–18.2 |
| Transgender womenm | 8 | 54.0\* | 27.9–80.0 | -- | -- | -- | 9 | 40.7\* | 19.0–62.4 |
| \_ |  |  |  |  |  |  |  |  |  |
| ***Total*** | ***186*** | ***22.5*** | ***19.5–25.6*** | ***207*** | ***14.9*** | ***12.9–16.8*** | ***246*** | ***18.1*** | ***15.9–20.2*** |
| Abbreviations: CI, confidence interval; MSM, men who have sex with men. |
| *Note:* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a “Unstable housing or homelessness” defined as experiencing unstable housing (i.e., moving in with others due to financial issues, moving 2 or more times, or being evicted at any time) or homelessness (living on the street, in a shelter, in a single-room–occupancy hotel, or in a car at any time) during the past 12 months. |
| b Unemployed persons included those who reported being unemployed at the time of the interview, excluding persons who were unable to work. |
| c “Hunger/food insecurity” defined as going without food due to lack of money during the past 12 months. |
| d Numbers are unweighted. |
| e Percentages are weighted percentages. |
| f CIs incorporate weighted percentages. |
| g Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. |
| h Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category. |
| i The National HIV/AIDS Strategy defines priority populations as populations that are disproportionately affected by HIV, and recommends that public health resources be delivered to priority populations for the greatest public health impact. For more information: https://www.hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025/ |
| j Cisgender men who had anal sex with cisgender men in the 12 months before interview. |
| k Priority population for youths includes persons aged 13-24 years; however, data from MMP are only available and presented for persons aged 18-24 years. |
| l Defined as people who injected drugs in the past 12 months. |
| m Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender. |

|  |
| --- |
| Table 22b. National HIV/AIDS Strategy indicators: Unstable housing or homelessness, unemployment, hunger/food insecurity during the 12 months before interview among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **Unstable housing or homelessnessa** | **Unemploymentb** | **Hunger/Food insecurityc** |
|  | **No.d** | **Row %e** | **95% CIf** | **No.d** | **Row %e** | **95% CIf** | **No.d** | **Row %e** | **95% CIf** |
| Cycle year |  |  |  |  |  |  |  |  |  |
| 2015 |  |  |  | 26 | 20.0 | 12.9–27.1 | 39 | 24.8 | 17.5–32.1 |
| 2016 |  |  |  | 40 | 18.0 | 12.5–23.5 | 32 | 16.4 | 10.9–21.9 |
| 2017 |  |  |  | 31 | 15.1 | 10.1–20.0 | 33 | 16.0 | 10.9–21.0 |
| 2018 | 40 | 18.1 | 12.3–23.8 | 21 | 10.2 | 5.7–14.6 | 37 | 20.2 | 13.5–26.9 |
| 2019 | 56 | 25.4 | 18.8–31.9 | 29 | 11.2 | 7.1–15.3 | 42 | 18.7 | 12.8–24.5 |
| 2020 | 55 | 27.0 | 20.6–33.3 | 38 | 18.1 | 12.7–23.5 | 40 | 18.4 | 13.1–23.7 |
| 2021 | 35 | 19.6 | 13.7–25.6 | 22 | 12.7 | 7.6–17.8 | 23 | 13.2 | 8.1–18.4 |
| Abbreviations: CI, confidence interval. |
| *Note:* Numbers might not add to total because of “don’t know” and skipped (missing) responses. Percentages might not sum to 100 because of rounding. |
| Excluded are estimates with a coefficient of variation ≥0.30 and those based on a denominator sample size <30. |
| Estimates with an absolute CI width ≥30, estimates with an absolute CI width between 5 and 30 and a relative CI width >130%, and estimates of 0% or 100% are marked with an asterisk (\*) and should be interpreted with caution. |
| a “Unstable housing or homelessness” defined as experiencing unstable housing (i.e., moving in with others due to financial issues, moving 2 or more times, or being evicted at any time) or homelessness (living on the street, in a shelter, in a single-room–occupancy hotel, or in a car at any time) during the past 12 months. |
| b Unemployed persons included those who reported being unemployed at the time of the interview, excluding persons who were unable to work. |
| c “Hunger/food insecurity” defined as going without food due to lack of money during the past 12 months. |
| d Numbers are unweighted. |
| e Percentages are weighted percentages. |
| f CIs incorporate weighted percentages. |

|  |
| --- |
| Table 23a. National HIV/AIDS Strategy indicators: Median HIV stigma scores during the 12 months before interview among persons with diagnosed HIV—Medical Monitoring Project, Georgia, 2015–2021 |
|  | **No.a** | **Medianb** | **95% CIc** |
| **Gender** |  |  |  |
| Cisgender male | 548 | 27.1 | 25.1–29.2 |
| Cisgender female | 187 | 34.8 | 30.4–39.3 |
| Transgenderd | 16 | 41.1 | 14.9–67.4 |
| **Sexual orientation** |  |  |  |
| Lesbian or gay | 332 | 24.8 | 22.5–27.1 |
| Heterosexual or straight | 314 | 33.9 | 30.7–37.1 |
| Bisexual | 76 | 27.1 | 22.8–31.4 |
| Other | 26 | 24.8 | 16.4–33.2 |
| **Race/ethnicity** |  |  |  |
| American Indian/Alaska Native | -- | -- | -- |
| Asian | -- | -- | -- |
| Black/African American | 563 | 29.5 | 27.3–31.7 |
| Hispanic/Latinoe | 37 | 30.1 | 15.6–44.6 |
| Native Hawaiian/other Pacific Islander | 0 | N/A | N/A |
| White | 114 | 24.5 | 21.0–27.9 |
| Multiple races | 36 | 34.0 | 20.6–47.3 |
| **Age at time of interview (years)** |  |  |  |
| 18–29 | 85 | 34.0 | 29.9–38.1 |
| 30–39 | 163 | 31.5 | 26.1–37.0 |
| 40–49 | 158 | 28.2 | 23.8–32.6 |
| ≥50 | 346 | 26.2 | 24.0–28.5 |
| **National HIV/AIDS Strategy priority populationsf** |  |  |  |
| All MSMg | 406 | 25.3 | 23.3–27.3 |
| Black/African American MSMg | 278 | 25.5 | 23.1–27.8 |
| Hispanic/Latino MSMe,g | 22 | 25.3 | 2.8–47.9 |
| American Indian/Alaska Native MSMg | -- | -- | -- |
| Persons aged 18-24 yearsh | 25 | 35.5 | 23.1–47.9 |
| People who inject drugsi | 10 | 20.4 | 9.4–31.4 |
| Black/African American cisgender women | 153 | 36.2 | 31.8–40.5 |
| Transgender womenj | 16 | 41.1 | 14.9–67.4 |
| \_ |  |  |  |
| ***Total*** | ***752*** | ***28.8*** | ***26.8–30.7*** |
| Abbreviations: CI, confidence interval; MSM, men who have sex with men. |
| *Note:* “Median HIV stigma score” defined as the weighted median score on a 10-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 dimensions of HIV stigma: personalized stigma during the past 12 months, current disclosure concerns, current negative self-image, and current perceived public attitudes about people living with HIV, measured among persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico. The HIV stigma scale used for this indicator is available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001277/table/T1/?report=objectonly [Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. J Adolesc Health 2007;40(1):96–98]. |
| Numbers might not add to total because of “don’t know” and skipped (missing) responses. |
| Excluded are estimates with a denominator sample size <30. |
| a Numbers are unweighted. |
| b Percentages are weighted percentages. |
| c CIs incorporate weighted percentages. |
| d Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. |
| e Hispanics or Latinos can be of any race. Persons are classified in only 1 race/ethnicity category. |
| f The National HIV/AIDS Strategy defines priority populations as populations that are disproportionately affected by HIV, and recommends that public health resources be delivered to priority populations for the greatest public health impact. For more information: https://www.hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025/ |
| g Cisgender men who had anal sex with cisgender men in the 12 months before interview. |
| h Priority population for youths includes persons aged 13-24 years; however, data from MMP are only available and presented for persons aged 18-24 years. |
| i Defined as people who injected drugs in the past 12 months. |
| j Persons were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender. |

|  |
| --- |
| Table 23b. National HIV/AIDS Strategy indicators: Median HIV stigma scores during the 12 months before interview among persons with diagnosed HIV, by cycle year—Medical Monitoring Project, Georgia, 2018-2021 |
|  | **No.a** | **Medianb** | **95% CIc** |
| **Cycle year** |  |  |  |
| 2018 | 169 | 28.4 | 23.2–33.6 |
| 2019 | 209 | 30.4 | 26.4–34.3 |
| 2020 | 192 | 27.7 | 23.6–31.9 |
| 2021 | 182 | 28.5 | 25.1–31.9 |
| Abbreviations: CI, confidence interval. |
| *Note:* “Median HIV stigma score” defined as the weighted median score on a 10-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 dimensions of HIV stigma: personalized stigma during the past 12 months, current disclosure concerns, current negative self-image, and current perceived public attitudes about people living with HIV, measured among persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico. The HIV stigma scale used for this indicator is available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001277/table/T1/?report=objectonly [Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. J Adolesc Health 2007;40(1):96–98]. HIV stigma estimates are not available prior to 2018 cycle year. |
| Numbers might not add to total because of “don’t know” and skipped (missing) responses. |
| Excluded are estimates based on a denominator sample size <30. |
| a Numbers are unweighted. |
| b Medians are weighted medians. |
| c CIs incorporate weights. |

|  |
| --- |
|  |
| APPENDIX: METHODS AND DEFINITIONS |
| METHODSThe Medical Monitoring Project (MMP) uses a stratified, 2-stage sampling design. States were sampled first, with probability proportional to size (PPS). All 50 states, the District of Columbia, and Puerto Rico (defined as primary sampling units [PSUs]) were eligible for selection. From these 52 PSUs, 20 were selected by using PPS sampling based on AIDS prevalence at the end of 2002. According to the PPS sampling method, states with a higher AIDS prevalence had a higher probability of selection, and those with a lower AIDS prevalence had a lower probability of selection [1]. Six municipal jurisdictions receive separate funding for HIV surveillance (Chicago, Illinois; Houston, Texas; Los Angeles County, California; New York City, New York; Philadelphia, Pennsylvania; and San Francisco, California); these areas were included with the state for first-stage sampling and constituted a city-state unit. If a state included a city with independent HIV surveillance authority (e.g., Texas, which includes Houston), selection of the state included selection of the city (i.e., city-state units were selected together). In 2004, 19 states (including the 6 separately funded areas within those states) and Puerto Rico were selected from the 52 PSUs, resulting in 26 MMP project areas. Because of funding constraints for the 2009 data collection cycle, 3 project areas (Maryland, Massachusetts, and South Carolina) were randomly selected to discontinue participation in MMP, and the total number of MMP areas was reduced to 23. An analysis carried out in 2014 found that the original measure of size with which states were originally sampled (i.e., AIDS prevalence in 2002) was still a reasonable proxy for the distribution of HIV prevalence in 2010 (the most recent year for which prevalence estimates were available at the time). Consequently, we concluded that the selected sample of states was still sufficiently representative of the population of persons with diagnosed HIV and that selecting a new sample for the 2015 and subsequent data collection cycles was unwarranted. In addition, the change in the sampling frame and the availability of national totals from the National HIV Surveillance System (NHSS) presented new options for calibrating weights, further lessening the need for any adjustments to the sample of states. At the second stage, persons with a reported diagnosis in NHSS were sampled after the selection of the states. The sampling frame was the national case surveillance data set containing records submitted to the Centers for Disease Control and Prevention (CDC) as of December 31, the year prior to the data collection cycle. This national data set was divided into 24 separate frame files according to the most recently reported residence information, with 1 frame for each of the 23 project areas and 1 residual file for all non-MMP project areas. Individuals were eligible for sampling if their vital status was alive, they were aged ≥18 years, and they were residents of the United States. Records in the NHSS are deidentified (under provisions of CDC’s Assurance of Confidentiality) and include only limited information about where the person currently resides, lacking the more exact address information contained in local case surveillance systems. CDC staff drew simple random samples from the 23 project area frame files, and project area staff then linked their samples to local case surveillance systems and extracted contact information for use in locating sampled persons, whom they then attempted to recruit.**Nonresponse Analysis and Weighting**Data used to generate national estimates were weighted for the probability of selection based upon known probabilities of selection of states and individuals within states. In addition, data were weighted to adjust for nonresponse by using predictors of response, including sex, race/ethnicity, age of most recent contact information, transmission category, and the person’s receipt of care as documented by laboratory test results in NHSS records. In 2016, frame data extracted from NHSS provided information for all sampled persons in MMP, regardless of response to the interview or from the medical record abstraction. These data provided descriptive information about all sampled persons for assessing how person characteristics were associated with nonresponse and were the source of data used for nonresponse analysis and weighting**Eligibility and Response Classifications**Persons were eligible for participation if, as of the sampling date, they had received a diagnosis of HIV, were aged ≥18 years, alive, and a resident of an MMP project area. Sampled persons were presumed to be eligible based on their information in NHSS unless data from another source contradicted this status. Persons were classified into 4 categories: (1) eligible respondents, (2) contacted nonrespondents, (3) nonrespondents who were not contacted, and (4) ineligible persons. These categories were used in calculating final response rates and contact rates in accordance with standard formulas [2]. **Weighting Overview**For the 2015–2021 MMP cycles, sets of weights at the national level of analysis were produced independently of the local levels of analysis. Base weights were applied, and statistical adjustments were then made for multiplicity and nonresponse at the person level. These nonresponse adjustments distributed the base weights of nonresponding persons to responding persons, so that the sum of the adjusted weights equaled the sum of the base weights. After adjusting for nonresponse, the weights were then poststratified to population totals from the NHSS frame. Extreme weights were trimmed and the weights were adjusted to the same population totals. For the weighting process, an updated sampling frame was created by returning to the source of surveillance records approximately a year later, during which time additional information may have become available for persons reported to NHSS and additional diagnoses may have been reported. This updated frame added to the frame all records that would have been eligible if their information had met the inclusion criteria; primarily, these were diagnoses that occurred during the year prior to the MMP sampling date (for the 2021 cycle, December 31, 2020), but had not yet been reported on the date the initial sample was drawn. Additionally, some persons were found to have had multiple records pertaining to them at the time of sampling, which were later identified as duplicate records. In some cases, updated information indicated that a person originally judged eligible and included on the original frame was ineligible. **Adjustments for unequal selection probabilities**The base weight was the inverse probability of selection for the person, which varied by project area. A person who was sampled from one jurisdiction but lived in another area at the time of sampling, retained the original base weight. Prior to weighting, such cross-jurisdictional records were grouped with their project area of residence at the time of sampling. This moving of records had no effect on the national weights, but did affect the project area weight totals, increasing some slightly while decreasing others. **Adjustments for multiplicity**A multiplicity factor was applied to the person weight for persons with records found to be present more than once when the original frame was compared to the updated frame. This factor, which accounts for some persons’ multiple opportunities for being sampled, was capped at 2.0 and was applicable for only 29 persons. **Adjustments for nonresponse**A nonresponse adjustment factor was then applied to the base weight. This factor makes use of information available for every sampled case from the NHSS frame data: personal demographics, HIV exposure category, laboratory data, and diagnosis data. Definitions of weighting classes were based on variables that were determined in bivariate analyses to be significantly related to response at the national or project area level. For the national adjustment factor, weighting classes were based on variables related to response: sex at birth, age of most recent contact information, and the person’s frequency of receipt of care (as indicated by NHSS records). For local project area data, the factors used for this adjustment varied, depending on the results of bivariate analyses. Within weighting classes, the adjustment for nonresponse was the ratio of the sum of the multiplicity-adjusted base weights for eligible sampled cases to the sum of these weights for eligible respondents. **Poststratification**The updated sampling frame provided information on the size and characteristics of the population with diagnosed HIV, which was used for poststratification to known distributions. A count of records on this updated frame provided an updated total population size estimate. Poststratifying to this total forced the sample-based estimate of population size to conform and corrected for late reports. This adjustment was performed within classes defined by key demographics (age, race/ethnicity, and gender), so that the weight sum was preserved in each class. **Trimming**After poststratification, the need for trimming the adjusted weights, so as not to inflate variance, was assessed. Where the design effect due to weighting (measured as 1 + CV2, where CV is the coefficient of variation of the weights) exceeded 1.75, we capped the weights at the median weight plus 4 times the interquartile range of the weights, then redistributed the excess to preserve the weight total. This was implemented in 4 project areas, but was not needed for national weights. The effect of other weighting adjustments, however, reduced weight totals through the exclusion of sampled persons found to be ineligible, while approximately maintaining the proportional distributions of the factors used in the poststratification. **Design variables and variance estimation**Nationally, design variables indicating strata and cluster membership for each participating person accounted for the sample design. Many states were sampled with certainty, because of their higher AIDS prevalence, and each of these was defined as its own stratum. Elsewhere, strata were created by grouping 2 to 3 states (PSUs in the stratified PPS design) that had similar selection probabilities. Multiple project areas within certainty states were effectively substrata, and each project area remained its own stratum. For certainty PSUs, the participant was the cluster. For the strata composed of noncertainty states, the state was the cluster. For local estimates, variance estimation was conditional on the initial sampling of states as PSUs, meaning that this stage of sampling was ignored. Participants were treated as having come from a simple random sample with replacement, although the various adjustment factors induced unequal weights.DEFINITIONS**Sociodemographic Characteristics**• **Gender:** Categories were male, female, and trans-gender. Participants were classified as transgender if reported sex at birth and current gender as reported by the participant were not the same or if the participant answered “transgender” to the inter-view question regarding self-identified gender. • **Health insurance, including coverage for antiretroviral therapy (ART) medications:** Participants were asked whether they had health insurance or coverage for ART medications during the 12 months before the interview. Responses to these questions were combined and categorized as private health insurance, Medicaid, Medicare, Ryan White HIV/AIDS Program, Tricare/ CHAMPUS and Veterans Administration coverage, insurance classified as other public health insurance, and unknown insurance. Participants could select more than 1 response for health insurance, including coverage for ART medications. • **Federal poverty guidelines:** Participants were asked about their combined monthly or yearly household income (in US$) from all sources during the 12 months before the interview. The number of persons meeting the current federal poverty threshold was determined by using the U.S. Department of Health and Human Services poverty guidelines that corresponded to the calendar year for which income was asked. These guidelines are issued yearly for the 48 contiguous states and Washington, D.C., and are an indicator used for determining eligibility for many federal and state programs. The 2015 guidelines [3] were used for participants interviewed in 2016, and the 2020 guidelines [4] were used for persons interviewed in 2021. Because the poverty guidelines are not defined for the territory of Puerto Rico, the guidelines for the contiguous states and Washington, D.C., were used for this jurisdiction. Participants were asked to specify the range of their income, and household income was assumed to be the midpoint of the income range. **Clinical Characteristics**• **CDC stage of disease classification for HIV infection:** Defined according to CDC’s 2014 revised surveillance case definition for HIV infection [5]. Information from NHSS was used to determine the most advanced HIV disease stage ever reached by participants. **Use of Health Care Services**• **Outpatient HIV medical care:** Defined as documentation of any of the following: encounter with an HIV care provider, viral load test result, CD4 test result, HIV resistance test or tropism assay, ART prescription, PCP prophylaxis, or MAC prophylaxis. All were measured through documentation in the person’s medical record; an encounter with an HIV care provider was also measured based on interview self-report. Persons were considered to be retained in care if they had 2 elements of outpatient HIV care at least 90 days apart in each 12-month period reviewed. • **ART prescription:** Defined as a prescription in the medical record, during the 12 months before the interview, of any of the following medications: abacavir, amprenavir, atazanavir, cobicistat, darunavir, delavirdine, didanosine, dolutegravir, efavirenz, elvitagravir, emtricitabine, enfuvirtide, etravirine, fosamprenavir, indinavir, lamivudine, lopinavir/ritonavir, maraviroc, nelfinavir, nevirapine, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir alafenamide, tenofovir disoproxil fumarate, tipranavir, or zidovudine. Persons with no medical record abstraction were considered to have no documentation of ART prescription. • ***Pneumocystis* pneumonia (PCP) prophylaxis:** Defined as documentation in the medical record that prophylaxis for PCP was prescribed among persons with a CD4 count of <200 cells/μL in the 12 months before the interview [6]. Persons prescribed regimens typically given as PCP prophylaxis (trimethoprim-sulfamethoxazole, dapsone with or without pyrimethamine and leucovorin, aerosolized pentamidine, and atovaquone) were not presumptively categorized as having received PCP prophylaxis unless this was specifically stated in the medical record or no length of time was specified for the course of treatment. • ***Mycobacterium avium* complex (MAC) prophylaxis:** Defined as documentation in the medical record that prophylaxis for MAC disease was prescribed among persons with a CD4 count of <50 cells/μL in the 12 months before the interview [6]. Persons prescribed regimens typically given as MAC prophylaxis (azithromycin with or without ethambutol and/or rifabutin, clarithromycin with or without ethambutol and/or rifabutin, and rifabutin with or without azithromycin or azithromycin along with ethambutol) were not presumptively categorized as having received MAC prophylaxis unless this was specifically stated in the medical record or no length of time was specified for the course of treatment. • **Influenza vaccination:** Participants were asked whether they had received seasonal influenza vaccine during the 12 months before the interview. • ***Neisseria gonorrhoeae* testing:** Defined as documentation in the medical record, during the 12 months before the interview, of a result from culture, Gram stain, enzyme immunoassay (EIA), nucleic acid amplification test (NAAT), or nucleic acid probe. • ***Chlamydia trachomatis* testing:** Defined as documentation in the medical record, during the 12 months before the interview, of a result from culture direct fluorescent antibody (DFA), EIA or enzyme-linked immunoassay (ELISA), NAAT, or nucleic acid probe. • **Syphilis testing:** Defined as documentation in the medical record, during the 12 months before the interview, of a result from nontreponemal serologic tests (rapid plasma reagin [RPR], Venereal Disease Research Laboratory [VDRL]), treponemal serologic tests (*Treponema pallidum* hemagglutination assay [TPHA], *T. pallidum* particle agglutination [TP-PA], microhemagglutination assay for antibodies to *T. pallidum* [MHA-TP], Chemiluminescence Immunoassay [CIA], fluorescent treponemal antibody absorption [FTA-ABS] tests), polymerase chain reactions (PCR), or dark-field microscopy. **Self-reported ART Medication Use and Adherence**• **ART adherence:** Participants were asked about their adherence to ART in the 30 days before the interview using questions from a 3-item scale developed by Wilson and colleagues [7]. Participants were asked about how many days they missed at least 1 dose of their HIV medicines, how often they took their HIV medicines in the way they were supposed to, and how good a job they did at taking their HIV medicines in the way they were supposed to during the 30 days before the interview. **Depression and Substance Use**• **Depression:** Participants were asked questions from the Patient Health Questionnaire (PHQ-8), an 8-item scale used to measure frequency of depressed mood in the preceding 2 weeks [8]. The PHQ-8 has the following question: “Over the last 2 weeks, how often have you been bothered by any of the following problems?” The respondent is then asked about the following problems: (1) little interest or pleasure in doing things (anhedonia); (2) feeling down, depressed, or hopeless; (3) trouble falling/staying asleep, or sleeping too much; (4) feeling tired or having little energy; (5) poor appetite or overeating; (6) feeling bad about yourself or that you are a failure or have let yourself or your family down; (7) trouble concentrating on things, such as reading the newspaper or watching television; and (8) moving or speaking so slowly that other people could have noticed, or being fidgety or restless or moving around a lot more than usual. Response categories were “not at all,” “several days,” “more than half the days,” and “nearly every day,” with points (0–3) assigned to each response category, respectively. The PHQ-8 responses were scored by using 2 methods. Method 1: an algorithm involving criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition (DSM-IV-TR) [9], for diagnosing major depression was used to classify adults with diagnosed HIV as having major depression, other depression, or no depression. To meet the criteria for major depression, a participant must have experienced 5 or more symptoms at least “more than half the days,” and one of the symptoms must be anhedonia or feelings of hopelessness. For other depression, a participant must have experienced 2 to 4 symptoms at least “more than half the days,” and one of the symptoms must be anhedonia or feelings of hopelessness. Method 2: scores for each response category were summed to produce a total score between 0 and 24 points. Current depression of moderate or severe intensity was defined as a total score of ≥10. • **Anxiety:** Participants were asked questions from the Generalized Anxiety Disorder Scale (GAD-7), a 7-item scale used to screen for and measure the severity of generalized anxiety disorder [10]. The GAD-7 has the following question: “Over the last 2 weeks, how often have you been bothered by any of the following problems?” The respondent is then asked about the following problems: (1) feeling nervous, anxious, or on edge; (2) not being able to stop or control worrying; (3) worrying too much about different things; (4) trouble relaxing; (5) being so restless that it is hard to sit still; (6) becoming easily annoyed or irritable; and (7) feeling afraid as if something awful might happen. Responses were scored according to criteria from the DSM-IV-TR [9]. Response categories were “not at all,” “several days,” “more than half the days,” and “nearly every day,” with points (0–3) assigned to each response category, respectively. Scores for each response category were summed to produce a total score between 0 and 21 points. “Severe anxiety” was defined as having a score of ≥15; “moderate anxiety” was defined as having a score of 10–14; and “mild anxiety” was defined as having a score of 5–9. • **Alcohol use:** Participants were asked about alcohol use during the 30 days and the 12 months before the interview. A drink was defined as 12 ounces of beer, a 5-ounce glass of wine, or a 1.5- ounce shot of liquor. • **Binge drinking:** Defined as ≥5 drinks in a single sitting for men and ≥4 drinks in a single sitting for women in the past 30 days. **Sexual Behavior****• Prevention modalities:** Reported behaviors that decrease the likelihood of HIV transmission to a sexual partner, including * Sex while sustainably virally suppressed: Vaginal or anal sex and the person’s HIV viral load was documented in the medical record as <200 copies/mL at every measure in the past 12 months before the interview.
* Condom-protected sex: Condoms were consistently used with at least 1 vaginal or anal sex partner.
* Condomless sex with a partner on preexposure prophylaxis (PrEP): At least 1 HIV-negative condomless-sex partner was on PrEP. PrEP use was only measured among the 5 most recent partners and was reported by the HIV-positive partner.
* Sex with an HIV-positive partner: Vaginal or anal sex with at least 1 HIV-positive partner.

• **High-risk sex:** Vaginal or anal sex with at least 1 HIV-negative or unknown status partner while not sustainably virally suppressed, when a condom was not used, and the partner was not known to be taking PrEP. **Met and Unmet Needs for Ancillary Services**• **Met need:** Defined as an ancillary service (e.g., HIV case management service, dental care, mental health service) received during the 12 months before the interview. • **Unmet need:** Defined as an ancillary service that the participant reported as needed, but not received, during the 12 months before the interview. **Division of HIV/AIDS Prevention National Indicators**Measures in this section are used by CDC’s Division of HIV/AIDS Prevention for national monitoring and evaluation purposes. • **Unstable housing or homelessness:** Persons were considered to have experienced unstable housing if they reported moving in with others due to financial issues, moving two or more times, or being evicted at any time during the past 12 months. Persons were considered to have experienced unstable housing or homelessness if they reported living on the street, in a shelter, in a single-room-occupancy hotel, or in a car during the past 12 months. Persons were considered to have experienced unstable housing or homelessness if they reported any form of unstable housing or homelessness during the past 12 months. The NHAS 2025 goal for unstable housing or homeless among PWH is 11%. • **Self-rated health:** Self-rated health is assessed by using a single question that captures the respondent’s general health at the time of interview and a Likert-type scale with the following responses: poor, fair, good, very good, or excellent. Self-rated health was dichotomized as good or better health (i.e., good, very good, or excellent) versus less than good health (i.e. poor, fair). The NHAS 2025 goal for self-rated health among PWH is 95%.• **Unemployment:** Unemployed persons included those who reported being unemployed at the time of interview, excluding persons who are unable to work. The NHAS 2025 goal for unemployment among PWH is 8%.• **Hunger/food insecurity:** Persons who reported being hungry and not eating because they did not have enough money for food during the past 12 months were considered to be food insecure. The NHAS 2025 goal for hunger/food security among PWH is 11%.• **Unmet needs for mental health services from a mental health professional among persons with diagnosed HIV who reported an unmet or met need for services from a mental health professional**: This measure was assessed through two questions. First, participants were asked if they saw or talked to a mental health professional (e.g., psychologist, psychiatrist, psychiatric nurse, or clinical social worker) about their health during the past 12 months. Next, they were asked if they needed to see or talk to a mental health professional about their health. The denominator represents people who needed mental health services (i.e., those with a met or unmet need), and was defined as those who received services (met need) and those who needed, but did not receive, services (unmet need). The numerator represents those who needed, but did not receive, services (unmet need). The NHAS 2025 goal for unmet needs for mental health services among those who needed services is 12% among PWH.• **HIV stigma:** Defined as the median score on a 10-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 dimensions of HIV stigma: personalized stigma, disclosure concerns, negative self-image, and perceived public attitudes about people with HIV [11].**ETHICS STATEMENT**In accordance with guidelines for defining public health research [12], CDC determined MMP was public health surveillance used for disease control, pro-gram, or policy purposes. Local institutional review board approval was obtained at participating states and territories when required. Informed consent was obtained from all interviewed participants. **REFERENCES**1. Frankel MR, McNaghten A, Shapiro MF, et al. A prob-ability sample for monitoring the HIV-infected popula-tion in care in the U.S. and in selected states. *Open AIDS J* 2012;6:67–76. doi:10.2174/1874613601206010067.2. The American Association for Public Opinion Research. Standard Definitions: Final dispositions of case codes and outcome rates for surveys. 9th ed. https://www.aapor.org/Standards-Ethics/Standard-Definitions-(1).aspx. Revised 2016. Accessed January 11, 2019.3. U.S. Department of Health and Human Services. 2015 Poverty guidelines. https://aspe.hhs.gov/2015-poverty-guidelines. Published 2015. Accessed January 2, 2019.4. U.S. Department of Health and Human Services. Computations for the 2021 Annual Update of the HHS Poverty Guidelines for the 48 Contiguous States and the District of Columbia. https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines/prior-hhs-poverty-guidelines-federal-register-references/2011-poverty-guidelines/2021-poverty-guidelines-computations-pages. Published 2022. Accessed September 21, 2023.5. CDC [Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI]. Revised surveillance case defini-tion for HIV infection—United States, 2014. *MMWR* 2014;63(RR-03):1–10. https://www.cdc.gov/mmwr/indrr\_2014.html. Accessed January 11, 2019.6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. https://go.usa.gov/vdGA. Updated October 25, 2018. Accessed January 11, 2019.7. Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a new three-item self-report measure for medication adherence. *AIDS Behav* 2016;20(11):2700–2708.8. Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the general population. *J Affect Disord* 2009;114(1–3):163–173. doi:10.1016/j.jad.2008.06.026.9. American Psychiatric Association. *Diagnostic and Sta-tistical Manual of Mental Disorders: DSM-IV-TR*. 4th ed. Washington, DC: American Psychiatric Associa-tion; 2000.10. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166(10):1092–1097.11. Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. *J Adolesc Health* 2007;40(1):96–98. doi:10.1016/j.jadohealth.2006.08.001.12. CDC. Distinguishing public health research and public health nonresearch. https://go.usa.gov/vdwz. Published July 2010. Accessed January 11, 2019. |

|  |
| --- |
|  |
| HIV/AIDS RESOURCES |



**Medical Monitoring Project**

[**https://www.cdc.gov/hiv/statistics/systems/mmp/index.html**](https://www.cdc.gov/hiv/statistics/systems/mmp/index.html)

 **Centers for Disease Control and Prevention**

[**http://www.cdc.gov/hiv/**](http://www.cdc.gov/hiv/)

 **Centers for Disease Control and Prevention**

[**http://www.cdc.gov/hiv/**](http://www.cdc.gov/hiv/)

 **Centers for Disease Control and Prevention**

[**http://www.cdc.gov/hiv/**](http://www.cdc.gov/hiv/)

 **Centers for Disease Control and Prevention**

[**http://www.cdc.gov/hiv/**](http://www.cdc.gov/hiv/)

**Georgia Department of Public Health**

[**http://dph.georgia.gov/what-hiv-and-aids**](http://dph.georgia.gov/what-hiv-and-aids)

**Georgia Department of Public Health**

[**http://dph.georgia.gov/what-hiv-and-aids**](http://dph.georgia.gov/what-hiv-and-aids)

**Georgia Department of Public Health**

[**http://dph.georgia.gov/what-hiv-and-aids**](http://dph.georgia.gov/what-hiv-and-aids)

**Georgia Department of Public Health**

[**http://dph.georgia.gov/what-hiv-and-aids**](http://dph.georgia.gov/what-hiv-and-aids)